



US 20080003605A1

(19) **United States**

(12) **Patent Application Publication**

Weigert et al.

(10) **Pub. No.: US 2008/0003605 A1**

(43) **Pub. Date: Jan. 3, 2008**

(54) **MICROARRAY ANALYSIS OF LIGHT CHAIN VARIABLE GENE EXPRESSION AND METHODS OF USE**

(75) Inventors: **Martin Weigert**, Chicago, IL (US);
Nathan Schoettler, Chicago, IL (US);
Dongyao Ni, Chicago, IL (US)

Correspondence Address:
MICHAEL BEST & FRIEDRICH LLP
ONE SOUTH PINCKNEY STREET
P O BOX 1806
MADISON, WI 53701 (US)

(73) Assignee: **THE UNIVERSITY OF CHICAGO**,
Chicago, IL (US)

(21) Appl. No.: **11/753,263**

(22) Filed: **May 24, 2007**

Related U.S. Application Data


(60) Provisional application No. 60/803,099, filed on May 24, 2006.

Publication Classification

(51) **Int. Cl.**
C12Q 1/68 (2006.01)
(52) **U.S. Cl.** **435/6**

(57) **ABSTRACT**

Disclosed are microarrays comprising a plurality of oligonucleotide species capable of hybridizing to a polynucleotide comprising a sequence encoding at least a portion of a light chain variable region or a complement thereof. Also disclosed are methods of identifying light chain variable genes associated with a disease, methods of diagnosing a disease and methods of monitoring a disease. Methods of evaluating the ability of a therapeutic agent or a treatment to alter expression of the light chain variable gene are also provided.






FIG. 1

Repertoire Differences in Healthy and Autoimmune-prone Mice




FIG. 2

Detection of L-chain Repertoire Differences After Induction of Autoimmunity




FIG. 3

Multiple Sclerosis Patient




FIG. 4




FIG. 5




FIG. 6

MICROARRAY ANALYSIS OF LIGHT CHAIN VARIABLE GENE EXPRESSION AND METHODS OF USE

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 60/803,099 filed on May 24, 2006, which is incorporated by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] Not applicable.

INTRODUCTION

[0003] Immunoglobulins are comprised of a heavy chain and a light chain. Both heavy chains and light chains are encoded by a series of gene segments that are rearranged by genomic recombination events that occur during B cell development. The resulting immunoglobulins are expressed on the cell surface as B cell receptors and may be secreted as antibodies. The genomic recombination events cause expression patterns of the various immunoglobulin gene segments to vary from one individual to another.

[0004] There are numerous pathologic conditions caused by the formation of auto-antibodies, which recognize self-antigens. In systemic autoimmune diseases, the immune system of an organism launches an immune response against the organism's own tissues, causing inflammation and tissue damage. Examples of diseases caused by immune dysfunction include rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, scleroderma, psoriasis, and Sjogren's syndrome. Additionally, there are other B cell related diseases in which immunoglobulin expression may play a role, such as multiple myeloma.

[0005] Relatively little is known about the role of light chain variable region expression in autoimmune diseases or other B cell related diseases. Thus, there is a need in the art for improved understanding of the relationship between immunoglobulin expression and disease.

SUMMARY

[0006] The present invention provides a microarray comprising a plurality of oligonucleotide species at least 20 nucleotides long and capable of hybridizing to a polynucleotide comprising a sequence that encodes at least a portion of a light chain variable (LCV) region, or a complement thereof.

[0007] Also provided is a method of characterizing the light chain variable gene expression in a subject. First, B cells are isolated from the subject and target polynucleotides are prepared from the B cells. Then target polynucleotides are hybridized to a microarray of the invention. Finally, light chain variable gene expression is characterized by detecting hybridization of the target polynucleotides to one or more oligonucleotide species.

[0008] In another aspect, the invention provides methods of identifying light chain variable genes associated with a disease by comparing the light chain variable gene expression in a first subject with the disease to the light chain variable gene expression in a second subject that does not

have the disease. The light chain variable gene expression can be assessed using a microarray according to the present invention. A difference in light chain variable gene expression between the first and the second subject indicating that expression of the light chain variable gene is associated with the disease.

[0009] In still another aspect, methods of monitoring a disease state in a subject are provided. The expression in the subject of a light chain variable gene associated with the disease is compared at two or more time points.

[0010] In a further aspect, methods of evaluating the effect of a therapy or a therapeutic agent on expression of a light chain variable gene associated with a disease in a subject are provided. The expression of the light chain variable gene in the subject is compared before and after treatment.

[0011] In a still further aspect, kits comprising the microarray are provided.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIG. 1 is a graph showing fluorescence intensity of labeled human B3 light chain DNA after hybridization to the human light chain variable genes.

[0013] FIG. 2 is a graph demonstrating the light chain variable gene repertoire differences in B6 56R transgenic mice as compared to Balb/c mice. The microarray fluorescent intensity data was normalized to the kappa constant region for each sample and then the Balb/c normalized values were subtracted from the B6 56R transgenic normalized values. A positive number indicates an over-representation of the light chain variable region in the B6 56R transgenic mouse.

[0014] FIG. 3 is a graph demonstrating the light chain variable gene repertoire differences in B6 56R transgenic mice before and after induction of autoimmunity. The microarray fluorescent intensity data were normalized to the kappa constant region for each sample.

[0015] FIG. 4 is a graph demonstrating the light chain variable expression in B cells harvested from the cerebral spinal fluid of a patient with multiple sclerosis. The data are normalized to the kappa constant region.

[0016] FIG. 5 is a graph demonstrating the overrepresentation of light chain variable genes in B cells isolated from the cerebral spinal fluid of an individual with multiple sclerosis normalized to light chain variable expression in B cells isolated from the cerebral spinal fluid of three individuals not suffering from an autoimmune disease.

[0017] FIG. 6 is a graph comparing the peripheral B cell repertoires of a healthy individual and a systemic lupus erythematosus (SLE) patient. The x-axis is the sum of the intensities for a given light chain gene in both samples. The y-axis is the ratio (SLE:healthy) of intensities between the samples. Global intensity dependent normalization was performed for each sample.

DETAILED DESCRIPTION

[0018] As described in detail below, the light chain variable gene repertoire expressed by an individual may provide information concerning that individual's risk of developing a disease, his prognosis, or his response to a particular

treatment. A light chain variable gene associated with a disease can be determined by comparing expression of light chain variable genes of individuals with the disease to the expression of light chain variable genes of individuals who do not have the disease, and identifying genes that are differentially expressed among a subpopulation of individuals with the disease.

[0019] The present invention provides a new approach to evaluating autoimmune disease using microarray analysis of light chain variable (V) gene usage. Microarrays suitable for use in this analysis include oligonucleotide species capable of hybridizing to a polynucleotide encoding at least a portion of an antibody light chain variable region, or to a complement thereof. Microarray analysis provides a rapid and relatively inexpensive method of characterizing light chain variable gene expression in a subject. By this method, the light chain variable repertoire of a subject can be determined. Information can be obtained by comparing light chain variable gene repertoires between subjects or by evaluating changes in expression in a single subject over time.

[0020] The light chain variable region repertoire of a subject refers to the light chain variable genes expressed by a subject. Characterization of the light chain variable gene repertoire includes, but is not limited to, detection and/or quantification of one or more of the light chain variable genes expressed in a subject. The subject can be any subject capable of expressing light chain variable genes, e.g. vertebrates. In the Examples, mouse and human subjects were used.

[0021] The methods of the invention can identify and distinguish light chain variable gene repertoires and provide information on relative expression of individual light chain variable genes in both humans and mice. This information is useful in identifying those light chain variable genes associated with a disease, such as autoimmune diseases or other B cell related diseases. Once a light chain variable gene is identified as being associated with a particular disease, the expression of that light chain variable gene can be used to diagnose the disease and to predict or assess the course of disease (e.g., severity, flares, or remission). The microarray may also be used to evaluate the effect of a therapy or therapeutic agent on expression of light chain variable genes associated with disease, or to predict an individual's response to treatment. Light chain variable gene expression may also be used to predict auto-antibody structures or susceptibility to autoimmune disease. Microarrays according to the invention may also allow evaluation of the overall immune system function and/or status of a subject.

[0022] Mouse models of systemic autoimmune diseases described below demonstrate that certain light chain V genes have unique properties and the expression of certain

sequences are associated with disease activity. Table 1 includes the light chain V regions of anti-DNA antibodies isolated from a mouse model of lupus. As can be seen in Table 1, these light chain variable regions have an unusually high frequency of acidic amino acids clustered in the complementarity determining regions (CDRs). Expression of these light chains in a subject with an autoimmune disease were studied using microarrays. Importantly, human counterparts to the mouse light chain variable genes discussed above have been identified, and were found to have similar structural features to those of mice (See Table 1, bottom panel). These light chains may also be important in autoimmune pathology, susceptibility and disease course in humans.

[0023] The human B2 gene encodes a κ III domain that displays four aspartic acids in a five amino acid segment of CDR1 (Table 1) and is thus of particular interest. A database of almost 300 human kappa light chain variable domain sequences derived from patients with monoclonal dyscrasias reveals no example of such an aspartic acid cluster, although studies suggest that B2 products are functional. One of the aspartic acids in B2 is located at amino acid position 31, which has been linked to the formation of amyloid fibrils in approximately 10% of patients with multiple myeloma. Specifically, mutations that generated an aspartic acid at position 31 are highly correlated with amyloid formation. Thus, light chain variable gene expression may also be related to symptomatology or sequelae of a disease such as multiple myeloma.

[0024] Subsets of light chain variable regions have been found to be associated with particular diseases as described in detail below. Briefly, auto-antibodies found in individuals with systemic autoimmune diseases such as lupus, rheumatoid arthritis and multiple sclerosis (MS) have a restricted light chain repertoire. These auto-antibodies appear to be associated with pathogenesis and/or correlate with disease activity in systemic autoimmune diseases. Knowledge of antibodies associated with pathogenesis will yield important information concerning the structure and expression patterns of these light chain variable genes. Light chain variable gene expression is also relevant to other diseases such as multiple myeloma and other B cell-related diseases.

[0025] The development of a rapid, sensitive, reliable and relatively inexpensive means of analyzing immunoglobulin light chain expression in subjects is needed to determine whether particular light chain variable genes are related to a particular disease. Development of such methods will allow for improved diagnosis of these diseases and may aid in determining disease prognosis and etiology, monitoring disease progression and evaluating therapeutic agents and treatment regimens.

TABLE 1

Comparison of mouse light chain V genes (top) identified in lupus models as having unique properties and human light chains (bottom) with similar properties. Highlighted are the relevant residues that confer autoreactivity.		
BT20	STTVTQSPASLSMAIGKVTIRCITSTDIDD---DMNWyQKPGEPKLLISE---	SEQ ID NO: 1
	GNTLRPGVPSRFSSSGYGTDFVFTIENMLSEVDVADYYCLQSDNLP---	

TABLE 1-continued

Comparison of mouse light chain V genes (top) identified in lupus models as having unique properties and human light chains (bottom) with similar properties. Highlighted are the relevant residues that confer autoreactivity.

BW20	ETTIVTQSPASLSVATGEKVTIRCITSTDIDD----DMNWFYQKPKGPEPPKLLISE---- GNTLRPGVPSRFRSSSGYGTDFVFTIENTLSEADVADYYCLQSDNMP----	SEQ ID NO: 2
GJ39C	DIQMTQSPSSLSASLGKVTITCKASQDINK----YIAWYQHKPKGPRLLIHY---- TSTLQPGIPSRFRSSSGSGRDYSFISINLEPEDIATYYCLQYDNLL----	SEQ ID NO: 3
VLX	QLVLTQ-SSSASFSLGASAKLTCTLSQHS---	SEQ ID NO: 4
YTI EW-		
YQQQ-		
PLKPP-		
KYVMELKKGSHSTGDGIPDRFSGSSSGADRYLSISNIQPEDEAIYIC GVGDTIKEQFV		
21-4	DIVLTQSPASLAVSLGQRATISCKASQSDYDGDSYMNWYQKPKGPPKILIYA---- ASNLESGIPARFRSSSGSGTDFTLNIHPVEEDAATYYCQSNEDP----	SEQ ID NO: 5
12-38	DIQMTQSPASLAASVGETVTITCRASENIYY----SLAWYQKQKSPQLLIYN---- ANSLEDGVP SRFRSSSGGTQYSMKINSMQPEDTATYFCKQAYDVP----	SEQ ID NO: 6
12-46	DIQMTQSPASLSVSVGETVTITCRASENIYS----NLAWYQKQKSPQLLVYA---- ATNLADGVP SRFRSSSGGTQYSLKINSLQSEDFGSYYCQHFPGT-----	SEQ ID NO: 7
08/018	DIQMTQSPSSLSASVGDRTITCQASQDISN--YLNWYQKYGKAPKLLIYDASN---- LETGVPSRFRSSSG--SGTDFTLTISLQPEDIAATYYCQYDNLP----	SEQ ID NO: 8
L25	EIVMTQSPATLSLSPGERATLSCRASQSVSSSY--LSWYQKPKGQAPRLLIYGAST---- RATGIPARFRSSSG--SGTDFTLTISLQPEDFAVYYCQDYNLN----	SEQ ID NO: 9
B2	ETTLTQSPAFMSATPGDKVNISCKASQDIDD--DMNWFYQKPKGAAIFIIQEATT---- LVPGIPPRFRSSSG--YGTDFTLTINNIESEDAAYFCLQHDNFP----	SEQ ID NO: 10
L11	AIQMTQSPSSLSASVGDRTITCRASQGI RN--DLGWYQKPKGKAPKLLIYAASS---- LQSGVPSRFRSSSG--SGTDFTLTISLQPEDFATYYCLQDYNYP----	SEQ ID NO: 11
L10	EIVMTQSPPTLSLSPGERVTLSCRASQSVSSSY--LWYQKPKGQAPRLLIYGAST---- RATSIPARESSSG--SGTDFTLTISLQPEDFAVYYCQDHNLP---	SEQ ID NO: 12
V2-19	SYELTQPSVSVSPGQTARITCSGDVLAKKY---ARWFQKYGQAPVLIYKDSE---- RPSGIPERFRSSSG--SGTTVTLTISGAQVEDEADYYCYSAADNNL---	SEQ ID NO: 13
V2-15	SYELTQLPSVSVSPGQTARITCSGDVLGENY---ADWYQKPKGQAPELVIYEDSE---- RYPGIPERFRSGST--SGNTTTLTISRVLTEDEADYYCLSGDEDNFP---	SEQ ID NO: 14
V5-4	QPVLTSQSSASASLGSVSKLTCTLSGHSS-- YIIAWHQKPKAPRYLMKLESGSYNKGSGVDRFRSSG-- SSGADRYLTISNLQFEDEADYYCETWDSNT----	SEQ ID NO: 15

[0026] The microarray of the present invention includes a plurality of oligonucleotide species capable of hybridizing to a polynucleotide comprising a sequence encoding at least a portion of an antibody light chain variable region, or a complement thereof. As described in the Examples below, a bioinformatics approach was used to select oligonucleotide sequences for use in the microarray from the variable regions of the 99 mouse and 82 human light chain variable genes. The oligonucleotide sequences were selected to minimize cross-hybridization with each of the other light chain variable genes. Generally, the oligonucleotide sequences selected were between 60 and 80 nucleotides long. Computer programs suitable for use in the selection process are described in detail in the Examples section. However, as one skilled in the art will appreciate, any suitable program for selecting oligonucleotide sequences can be used, and many different programs are known to those of skill in the art. The light chain variable regions from all species identified to date are similar in structure such that one of skill in the art

would expect the microarray and methods described herein could be adapted for use in any species capable of producing antibodies.

[0027] The human and mouse light chain variable gene specific oligonucleotides listed in Table 2 and Table 3, respectively, were selected from the germline sequences for the genes based on several criteria. The oligonucleotides were chosen from the most variable regions of each light chain variable gene, and were selected to be sufficiently unique to allow identification of individual light chain variable regions with minimal cross-hybridization. The oligonucleotides were also selected to maximize the likelihood that all of the sequences would hybridize to their target sequences under similar conditions by choosing a group of oligonucleotides that have similar G-C content and similar melting temperatures. Finally, oligonucleotides that have a low potential to self-fold were selected. Any suitable criteria

could be used to select oligonucleotides for use in the microarray. Additional potential oligonucleotides are listed in Tables 4 and 5.

[0028] One of skill in the art will appreciate that the present invention is not limited to the oligonucleotides listed in Tables 2-5. Additional oligonucleotides for use in the microarray and methods of the invention include, but are not limited to, the complements of the oligonucleotides listed in the Tables, oligonucleotides substantially similar to the oligonucleotides listed in the Tables and any other oligonucleotides derived from the germline sequences of the light chain variable regions. The light chain variable region gene sequences are publicly available in GenBank under the heading "Ig Germline Genes". "Substantially similar oligonucleotides" includes oligonucleotides with at least 90% nucleotide identity to the oligonucleotides of Table 2-5. Suitably the oligonucleotides have at least 95% nucleotide identity to the oligonucleotides of Tables 2-5. Also included are light chain variable oligonucleotides containing portions of the sequences of the oligonucleotides listed in Tables 2-5.

[0029] In the Examples, oligonucleotides between 60 and 80 nucleotides long were used to minimize cross-hybridization with multiple light chain variable regions. One of skill

in the art would appreciate that shorter or longer oligonucleotides could be used. Use of shorter oligonucleotides may result in a loss of specificity for a single light chain variable region, but such a loss of specificity can be compensated for by selecting and using multiple shorter oligonucleotides for each light chain variable region and then using a computer program that compensates for the cross-hybridization in the analysis of the microarray data. For example, the oligonucleotides included in the microarray may suitably be at least 20 nucleotides long, 30 nucleotides long, 40 nucleotides long, 50 nucleotides long, 60 nucleotides long, 70 nucleotides long, 80 nucleotides long, or 100 nucleotides long. Quantification of cross-hybridization between light chain variable region oligonucleotides and all target polynucleotides can be tested using target polynucleotides complementary to each of the oligonucleotide species on the microarray. These target polynucleotides may be synthetically produced or produced from B cell clones expressing known light chain variable regions. The results from such cross-hybridization experiments can then be applied to experimental data to eliminate experimental artifacts due to cross-hybridization. Other methods to minimize or compensate for cross-hybridization may also be used as would be apparent to those of skill in the art.

TABLE 2

Human light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Gene	Sequence	
A17/A1	CTGCAGGCTAGTCAAAGCCTCGTATACAGTGATGGAAACACCTACTTGAATTGG TTTCAGCAGAGG	SEQ ID NO: 16
A10	CTCACCATCAATAGCCTGGAAGCTGAAGATGCTGCAACGTATTACTGTGCATCAGA GTAGTAGTTTAC	SEQ ID NO: 17
A27/A11	GACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGATTACT GTCAGCAGTATG	SEQ ID NO: 18
A14	GATCTGGGACAGATTTTACCTTTACCATCAGTAGCCTGGAAGCTGAAGATGCTGC AACATATTACTG	SEQ ID NO: 19
A2/A18b	CATCTCTGCAAGTCTAGTCAGAGCCTCCTGCATAGTGATGGAAAGACCTATTTG TATTGGTACCTG	SEQ ID NO: 20
A3/A19	GATCAGGCACAGATTTTACTACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTG GGGTTTATTACTG	SEQ ID NO: 21
L14/A20	TCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCGAGTCAGGGCATT AGCAATTATTTAG	SEQ ID NO: 22
A23	CTACTTGAGTTGGCTTCAGCAGAGGCGAGGCCAGCCTCCAAGACTGCTAATTTAT AAGATTTCTAAC	SEQ ID NO: 23
A30	CTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACA GCATAATAGTTA	SEQ ID NO: 24
A7	CATCTCCTTCAGGCTAGTCAAAGCCTCGTACACAGTGATGGAAACACCTACTTG AGTTGGCTTCAG	SEQ ID NO: 25
B2	GAGAAGCTGCTATTTTCATTATTCAAGAAGCTACTAGTCTCGTTCTGGAATCCC ACCTCGATTACG	SEQ ID NO: 26
B3	CATCAACTGCAAGTCCAGCCAGAGTGTATTTATACAGCTCCAACAATAAGAACTA CTTAGCTTGGTAC	SEQ ID NO: 27
L1	GTAGGAGACAGAGTCACCATCACTTGTCTGGGCGAGTCAGGGCATTAGCAATTAT TTAGCCTGGTTTC	SEQ ID NO: 28

TABLE 2-continued

Human light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Gene	Sequence	
L10	CTCACCATCAGCAGCCTGCAGCCTGAAGATTTGTCAGTTATTACTGTCTAGGAGG ATCATAACTTAC	SEQ ID NO: 29
L11	CTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTGCAACTTATTACTGTCTACA AGATTACAATTA	SEQ ID NO: 30
L12	TGGTATCAGCAGAAACCAGGAAAGCCCTAAGCTCCTGATCTATGATGCCTCC AGTTTGAAAGTG	SEQ ID NO: 31
L15	CTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTGCAACTTATTACTGCCAACA GTATAATAGTTA	SEQ ID NO: 32
L2/L16	CTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTGTCAGTTATTACTGTCTAGCA GTATAATAACTG	SEQ ID NO: 33
L14/18a/L18	TGGTATCAGCAGAAACCAGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCC AGTTTGAAAGTG	SEQ ID NO: 34
L19	CATCTTCTGTGTCATCTGTAGGAGACAGAGTCACCATCACTTGTCTGGGCGAG TCAGGGTATTAG	SEQ ID NO: 35
L6/L20	TTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTGTCAGTTATTACTGTCTC AGCAGCGTAGCA	SEQ ID NO: 36
L22	GTAGGAGACAGAGTCAGTATCATTGCTGGCAAGTGAGGGCATTAGCAGTAAT TTAGCCTGGTATC	SEQ ID NO: 37
L23	CTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTGCAACTTATTACTGTCAACA GTATTATAGTAC	SEQ ID NO: 38
L24	CATCTACAGGAGACAGAGTCACCATCAGTTGTCGGATGAGTCAGGGCATTAGCA GTTATTTAGCCTG	SEQ ID NO: 39
L25	CTCACCATCAGCAGCCTGCAGCCTGAAGATTTGTCAGTTATTACTGTCTAGCAGG ATTATAACTTAC	SEQ ID NO: 40
L5	GACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTGCAACTTAC TATTGTCAACAG	SEQ ID NO: 41
L8	CTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTGCAACTTATTACTGTCAACA GCTTAATAGTTA	SEQ ID NO: 42
L9	CATCTACAGGAGACAGAGTCACCATCACTTGTCTGGGCGAGTCAGGGTATTAGCA GTTATTTAGCCTG	SEQ ID NO: 43
O11/O1-72	GTCTAGTCAGAGCCTCTTGGATAGTGATGATGAAACACCTATTTGGACTGGTAC CTGCAGAAGCCA	SEQ ID NO: 44
O2/O12	GAGCATTAGCAGCTATTAAATTGGTATCAGCAGAAACCAGGAAAGCCCTAA GCTCCTGATCTAT	SEQ ID NO: 45
O4/O14	CAGTTATTTAAATTGGTATCGGCAGAAACCAGGAAAGTTCCTAAGCTCCTGATC TATAGTGCATCC	SEQ ID NO: 46
O8/O18	GTAGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTAT TTAAATTGGTATC	SEQ ID NO: 47
V1-11	GCAGAGGGTCACCATCTCTGTTCTGGAAGCAGCTCCAACATCGGAAATAATGC TGTAACCTGGTAC	SEQ ID NO: 48
V1-16	GCAGAGGGTCACCATCTCTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATACT GTAACCTGGTAC	SEQ ID NO: 49
V1-17	GCAGAGGGTCACCATCTCTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATTAT GTATACTGGTAC	SEQ ID NO: 50
V1-18	CTCCCTGGCCATCACTGGACTCCAGTCTGAGGATGAGGCTGATTATTACTGCAAA GCATGGGATAAC	SEQ ID NO: 51
V1-19	CAAACCTCTCATTTATGACAATAATAAGCAGCCCTCAGGGATTCTGACCGATTCC TCTGGCTCCAAG	SEQ ID NO: 52

TABLE 2-continued

Human light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Gene	Sequence	
V1-2	GTCAGTCACCATCTCCTGCACCTGGAACCAGCAGTGACGTTGGTGGTTATAACTAT GTCTCCTGGTAC	SEQ ID NO: 53
V1-20	CCACCCCTCCAAACTCCTATCCTACAGGAATAACAACCGGCCCTCAGGGATCTCA GAGAGATTCTCT	SEQ ID NO: 54
V1-22	CTGTGATCTATGAGGATAACCAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGG CTCCATCGACAG	SEQ ID NO: 55
V1-3	GTCAGTCACCATCTCCTGCACCTGGAACCAGCAGTGATGTTGGTGGTTATAACTAT GTCTCCTGGTAC	SEQ ID NO: 56
V1-4	CAAACCTCATGATTTATGAGGTCAGTAATCGGCCCTCAGGGGTTCTAATCGCTTC TCTGGCTCCAAG	SEQ ID NO: 57
V1-5	CTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTTATATACAAGC AGCAGCACTTTC	SEQ ID NO: 58
V1-7	CTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCCTCAT ATGCAGGTAGTAG	SEQ ID NO: 59
V1-9	CTCTGGGCTCAAGTCCGAGGTTGAGGCTAATTATCACTGCAGCTTATATTCAAGT AGTTACACTTTC	SEQ ID NO: 60
V2-1	GATAAATATGCTTGCTGGTATCAGCAGAAGCCAGGCCAGTCCCTGTGCTGGTCA TCTATCAAGATAG	SEQ ID NO: 61
V2-11	TAGTCACATTGACCATCAGTGGAGTCCAGGCAGAAGACGAGGCTGACTATTACT GTCTATCAGCAGA	SEQ ID NO: 62
V2-13	CTTGGGACAGACAGTCCAGGATCACATGCCAAGGAGACAGCCTCAGAAGCTATTA TGCAAGCTGGTAC	SEQ ID NO: 63
V2-15	CTGAGTTGGTGATATACGAAGATAGTGAGCGGTACCCTGGAATCCCTGAACGAT TCTCTGGGTCCAC	SEQ ID NO: 64
V2-17	GACAACAGTCACGTTGACCATCAGTGGAGTCCAGGCAGAAGATGAGGCTGACTA TTACTGTCAATCAG	SEQ ID NO: 65
V2-6	CTGGGACAGACGGCCAGGATTACCTGTGGGGAAACAACATTGGAAGTAAAAAT GTGCACCTGGTACC	SEQ ID NO: 66
V3-2	GTTACTATCCAAACTGGTTCCAGCAGAAACCTGGACAAGCACCCAGGGCACTGA TTTATAGTACAAG	SEQ ID NO: 67
V3-3	GACACTGATTTATGATAGAAGCAACAACACTCCTGGACACCTGCCGGTTCTCA GGCTCCCTCCTT	SEQ ID NO: 68
V3-4	CTGGAGGACAGTCACTCACTTGTGGCTTGAGCTCTGGCTCAGTCTCTACTAG TTACTACCCAG	SEQ ID NO: 69
V4-1	AATACAGGGATTTTACTCATCTCCGGCTCCAGTCTGAGGATGAGGCTGACTATT ACTGTATGATTT	SEQ ID NO: 70
V4-2	AATGCAGGGATTTTACTCATCTCTGGCTCCAGTCTGAGGATGAGGCTGACTATT ACTGTATGATTT	SEQ ID NO: 71
V4-3	AATGCAGGGATTTTACTCATCTCTGGCTCCAGTCTGAGGATGAGGCTGACTATT ACTGTATGATTT	SEQ ID NO: 72
V4-4	GGTACCAACAAAAGCCAGGGAACCTCCCGGTATCTCTGTACTACCCTCAG ACTCCAATAAGGG	SEQ ID NO: 73
V4-6	GTACCAGCAGAAGCCAGGGAGCTCTCCAGGTTATTCCTGTACTACTACTCAGAC TCAGACAAGCAG	SEQ ID NO: 74
V5-1	CATCGAATGGTATCAACAGAGACCAGGGAGGTCCCCCAGTATATAATGAAGGT TAAGAGTGATGGC	SEQ ID NO: 75

TABLE 2-continued

Human light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Gene	Sequence	
V5-2	GAATCGGTACCTGACCATCAAGAACATCCAGGAAGAAGATGAGAGTGACTACCA CTGTGGGGCAGAC	SEQ ID NO: 76
V5-4	CTACCTCACCATCTCCAACCTCCAGTTTGAGGATGAGGCTGATTATTACTGTGAG ACCTGGGACAGT	SEQ ID NO: 77
V1-13_146	TCATCTATGGTAAACAGCAATCGGCCCTCAGGGTCCCTGACCGATTCTCTGGCTC CAAGTCTGGCACCTCA	SEQ ID NO: 78
V2-14_127	CCTGTGCTGGTFCGTCTATGATGATAGCGACCGGCCCTCAGGATCCCTGAGCGAT TCTCTGGCTCCAACCT	SEQ ID NO: 79
V2-19_209	TCACCTTGACCATCAGCGGGGCCAGGTTGAGGATGAGGCTGACTATTACTGTTA CTCTGCGGCTGACAACA	SEQ ID NO: 80
V2-7_150	CAGCAAACGACCCCTCCGGGATCCCTGAGAGATTCTCTGGCTCCAGCTCAGGGAC AATGGCCACCTTGACTATC	SEQ ID NO: 81
V2-8_129	TGTGCTGGTCATCTATAGCGATAGCAACCGGCCCTCAGGGATCCCTGAGCGATTCT TCTGGCTCCAACCCAG	SEQ ID NO: 82
V5-6_121	GAGAAGGGCCCTCGGTACTTGATGAAGCTTAACAGTGATGGCAGCCACAGCAAG GGGACGGGATCCCTGATC	SEQ ID NO: 83
actin_beta	TTTTAATAGTCATTCCAAATATGAGATGCGTTGTTACAGGAAGTCCCTTGCCATC CTAAAAGCCACC	SEQ ID NO: 84
CD19	GCTGTGACTTTGGCTTATGTGATCTTCTGCCCTGTGTTCCCTTGTGGGCATTCTTCA TCTTCAAAGAG	SEQ ID NO: 85
CD20	CAATACAGAACCATTCCATTATCTTTGTACAGGGCTGACATTGTGGCACATTC TTAGAGTTACCA	SEQ ID NO: 86
hk_con	GAATAACTTCTATCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCT CCAATCGGGTAAC	SEQ ID NO: 87

[0030]

TABLE 3

Mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Gene	Sequence	
12-38	CTGGGACACAGTATTCTATGAAGATCAACAGCATGCAGCCTGAAGATACCGCA ACTTATTTCTGTAAACA	SEQ ID NO: 88
12-41	GCAAAAACCTTAGCAGATGGTGTGCCATCAAGGTTCAAGTGGCAGTGGATCAGG AACACAATATTCTCTCA	SEQ ID NO: 89
12-44	AGTTTTCTCTGAAGATCAACAGCCTGCAGCCTGAAGATTTGGGAGTTATTACT GTCAACATCATTATGG	SEQ ID NO: 90
12-46	GCAACAAACTTAGCAGATGGTGTGCCATCAAGGTTCAAGTGGCAGTGGATCAGG CACACAGTATTCCTCA	SEQ ID NO: 91
19-13	TTTCACTCTCACCATCAGCAATATGCAGTCTGAAGACCTGGCAGATTATTTCTG CCAGCAATATAGCAGC	SEQ ID NO: 92
19-14	CTCTCACCATTAGCAATGTGCAATCTGAAGACCTGGCAGATTATTTCTGTCTGC AACATTGGAATTATCC	SEQ ID NO: 93
19-15	GGTACTAATGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAAGCACT GATTTACTCGGCATCCT	SEQ ID NO: 94

TABLE 3-continued

Mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.	
Gene	Sequence
19-17	GGACGGATTTCACCTTTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTT SEQ ID NO: 95 TATTACTGTCAGCAACA
19-20	CACTGGGGTCCCCTGATCGCTTCACAGGCAGTGGATCTGCAACAGATTTCACTCT SEQ ID NO: 96 GACCATCAGCAGTGTG
19-23	CTCTCACCATTAGCAATGTGCAGTCTGAAGACTTGGCAGATTATTTCTGTGAGC SEQ ID NO: 97 AATATAGCAGCTATCC
19-25	TATACCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCACTTTATTACTGT SEQ ID NO: 98 CAGCAACATTATAGCA
19-29	ACCCTGGGGTCCCCTGATCGCTTCACAGGCAGTGGATCTGCAACAGATTTCACTC SEQ ID NO: 99 TGACCATCAGCAGTCT
19-32	ATTCTGCTTGTATCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTC SEQ ID NO: 100 AGAGTGTGAGTAATGAT
21-1	CACCATCTCCTGCAGAGCCAGTGAAGTGTGAATATTATGGCACAAGTTTAA SEQ ID NO: 101 TGCAGTGGTACCAACAG
21-10	TCACCCTCACCATTGATCTGTGGAGGCTGATGATGCTGCAACCTATTACTGTC SEQ ID NO: 102 AGCAAAATAATGAGGA
21-12	CTGGCTATAGTTTATATGCACTGGTACCAACAGAAACCAGGACAGCCACCCAAA SEQ ID NO: 103 CTCCTCATCTATCTTGC
21-2	GCCACCATCTCCTGCAGAGCCAGCGAAAGTGTGATAATTATGGCATTAGTTTT SEQ ID NO: 104 ATGAACTGGTTCCAAC
21-3	GAGCCACTATCTTCTGCAGAGCCAGCCAGAGTGTGATTATAATGGAATTAGT SEQ ID NO: 105 TATATGCACTGGTTCCA
21-4	GCCACCATCTCCTGCAGAGCCAGCCAAAGTGTGATTATGATGGTGTAGTTAT SEQ ID NO: 106 ATGAACTGGTACCAAC
21-5	CTCACCATTAACTCTGTGGAGGCTGATGATGTTGCAACCTATTACTGTCAGCAA SEQ ID NO: 107 AGTAATGAGGATCCTC
21-7	CTAGCTATAGTTTATATGCACTGGTACCAACAGAAACCAGGACAGCCACCCAAA SEQ ID NO: 108 CTCCTCATCAAGTATGC
21-9	GACAGAGGGCCACCATATCTGCAAGCCAGCGAAAGTGTGAGTTTGTGCTGGT SEQ ID NO: 109 ACAAGTTTAAATGCACTG
22-33	AGTAAGAAGGTCACCATTAGTTGCACGGCCAGTGAAGCCCTTTATTCAAGCAA SEQ ID NO: 110 ACACAAGGTGCACTACT
23-37	GATTACACTCTCAGTATCAACAGTGTGAAGCCCGAAGATGAAGGAATATATTA SEQ ID NO: 111 CTGTCTTCAAGGTACA
23-39	CTCTCAGTATCAACAGTGTGGAACCTGAAGATGTTGGAGTGTATTACTGTCAA SEQ ID NO: 112 AATGGTCCACAGCTTCC
23-43	CAGGAGATAGCGTCAGTCTTCTCAGGGCCAGCCAAAGTATTAGCAACAAC SEQ ID NO: 113 CTACACTGGTATCAACA
23-45	GGAGATAGAGTCAGTCTTCTCAGGGCCAGTCAAAGTATTAGCAACTACCT SEQ ID NO: 114 ACACTGGTATCAACAAA
23-48	TTCTCCTGCAGGGCCAGTCAAGCATTTGGCACAAGCATACTGGTATCAGCA SEQ ID NO: 115 AAGAACAATGGTTCTC
4-50	GTAAGTGGTACCAGCAGAAGTCAGATGCCTCCCCAAACTATGGATTTATTACA SEQ ID NO: 116 CATCCAACCTGGCTCCT
4-51	GGGGCTGGGATCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAAATGA SEQ ID NO: 117 TGCAACTTATTACTGCC
4-57	TGTCTGCATCTCCAGGGGAAAAGTCCACCATGACCTGCAGGGCCAGCTCAAGT SEQ ID NO: 118 GTAAGTCCAGTACTT

TABLE 3-continued

Mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.	
Gene	Sequence
8-16	ATCAGAAATCTTTTATGGAGTGAAACCAAAGGTACTGTTTGGTCTGGCACCAG SEQ ID NO: 119 TGAAACCAGGGCAAAC
8-19	CTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGA SEQ ID NO: 120 ATGATTATAGTTATCC
8-21	GGTCACTATGAGCTGCAAATCCAGTCAGAGTCTGCTCAACAGTAGAACCCGAA SEQ ID NO: 121 AGAACTACTTGGCTTGG
8-24	TCCTCCCTGGCTATGTCAGTAGGACAGAAGGTCACTATGAGCTGCAAGTCCAG SEQ ID NO: 122 TCAGAGCCTTTTAAATA
8-27	GAAAAGTCACTATGAGCTGTAAGTCCAGTCAAAGTGTTTTATACAGTTCAA SEQ ID NO: 123 TCAGAAGAACTACTTGG
8-28	CCGATTTCACTCTTACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATT SEQ ID NO: 124 ACTGTCAGAATGATCA
8-30	CCCTAGCTGTGTCAGTTGGAGAGAAGGTTACTATGAGCTGCAAGTCCAGTCAG SEQ ID NO: 125 AGCCTTTTATATAGTAG
8-34	TAGCTAGTGGCAACCAAAATAACTACTTGGCCTGGCACCAGCAGAAACCAGGA SEQ ID NO: 126 CGATCTCCTAAAATGCT
RF	GAGAAACCTGGGAAAATAAATAAGCTTCTTATCTACTCTGGATCCACTTTGCAA SEQ ID NO: 127 TCTGGAATTCATCAA
VL1	AACTATGCCAACTGGGTCCAAGAAAAAGCAGATCATTATTCACTGGTCTAAT SEQ ID NO: 128 AGGTGGTACCAACAACC
VL2	TAActATGCCAACTGGGTCCAAGAAAAACCAGATCATTATTCACTGGTCTAAT SEQ ID NO: 129 AGGTGGTACCAACAACC
VLx	ACAGCCACTCAAGCCTCCTAAGTATGTGATGGAGCTTAAGAAAGATGGAAGCC SEQ ID NO: 130 ACAGCACAGGTGATGGG
aa4	CTCAAGTGAAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCTCCCCCA SEQ ID NO: 131 AACCTGGATTTATCGC
ac4	TCAGATCAGCAGCATGGAGGCTGAAGATGTTGCCACTTATTACTGTTTTCAGG SEQ ID NO: 132 GGAGTGGTACCCACT
ad4	TATTCTTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTTTACTGTC SEQ ID NO: 133 CAGCAGTACAGTGGTT
ae4	ACTCTCTACAATCAGCAGCATGGAGGCTGAAGATGCTGCCTCTTATTTCTGCC SEQ ID NO: 134 ATCAGTGGAGTAGTTA
af4	CAATCATGCTGCATCTCTAGGGGAGGAGATCACCTAACCTGCAGTGCCAGC SEQ ID NO: 135 TCGAGTGAAGTTACAT
ag4	CACCTTACCAAATTCGTGATTTATAGGACATCCAACCTGGCTTCAGAAGTCCC SEQ ID NO: 136 AGCTCCCTTCAGTGGC
ah4	TACTTGTACTGGTACCAGCAGAAGTCAGGATCCTCCCCAAAACCTCTGGATTTAT SEQ ID NO: 137 AGCATATCCAACCTGG
ai4	CTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAC SEQ ID NO: 138 CAGTATCATCGTTCCCC
aj4	TACATGTAATGGTTCCAGCAGAAGCGAGGATCCTCCCCAAAACCTCTGGATTTAT SEQ ID NO: 139 AGCATATCCAACCTGG
al4	CATGCACTGGTACCAGCAGAAGCCAGGATCCTCCCCAGACTCTGGATTTATTT SEQ ID NO: 140 AACATTCAACTTGGCT
am4	TTGTTCTCTCCAGTCTCCAGCAATCCTGTCTGCATCTCCAGGGGAGAAGGTCA SEQ ID NO: 141 CAATGACTTGCAGGGC

TABLE 3-continued

Mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.	
Gene	Sequence
an4	GACATCTTCTCTTTCACAATCAACAGCATGGAGGCTGAAGATGTTGCCACTTA SEQ ID NO: 142 TTACTGTCAGCAAAGG
ap4	GCCAGCTCAAGTGTAAAGTTACATGCACTGGTTCAGCAGAAGCCAGGCCTTC SEQ ID NO: 143 TCCCAAACCTCTGGATTT
aq4	GTAAGTTACATGTACTGGTACCAGCAGAAGCCAAGATCCTCCCCAAACCTG SEQ ID NO: 144 GATTTATCTCACATCCA
ar4	TGTAAGTTACATGTACAGGTACCAGCAGAAGCCAGGATCCTCACCCAAACCT SEQ ID NO: 145 GGATTTATGGCACATCC
at4	GTAAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCTCCCCAGACTCCT SEQ ID NO: 146 GATTTATGACACATCCA
ay4	GGTCTGAGAGCTCTTACACTCTGACAATCAGCTGCATGCAGGACGAAGTTGCT SEQ ID NO: 147 GCCACTTACTATTGTCA
ba4	CCATGTATGCATCTCTAGGAGAGAGAGTCACTATCACTTGCAAGGCGAGTCAG SEQ ID NO: 148 GACATTAATAGCTATTT
bb1	CACCTATTTACATGGTACCTGCAGAAGCCAGGCCAGTCTCCAAGCTCCTGAT SEQ ID NO: 149 CTACAAAGTTTCCAAC
bb1.1	AATGGAACACCTATTTATATGGTACCTGCAGAAGCCAGGCCAGTCTCCAAA SEQ ID NO: 150 GCTCCTGATCTACAGGG
bd2	GTGAGAGCCCTCTTAGATAGTGATGGAAGACATATTTGAATTGGTTGTTACAG SEQ ID NO: 151 AGCCAGGCCAGTCTCC
bi2	TTACAACAGAGGCTGGCCAGGCTCCAAAGCACCTAATGTATCAGGTGTCCAA SEQ ID NO: 152 ACTGGACCTGGCATCC
bj2	ATATAGTAATGGAACCTATTTGAATTGGTTATTACAGAGCCAGGCCAGT SEQ ID NO: 153 CTCCAAAGCCCTAATC
b11	CAGGTCTAGTCAGAGCCTTGAAAACAGTAATGGAACACCTATTTGAACTGGT SEQ ID NO: 154 ACCTCCAGAACCAGGC
bt20	CATCCCTGTCCATGGCTATAGGAGAAAAAGTCACCATCAGATGCATAACCAGC SEQ ID NO: 155 ACTGATATTGATGATGA
bv9	ACATTGGTAGTAGCTTAAACTGGCTTCAGCAGGAACCAGATGGAACCTATTAAA SEQ ID NO: 156 CGCCTGATCTACGCCAC
bw20	CTGTCCGTGGCTACAGGAGAAAAAGTCACTATCAGATGCATAACCAGCACTG SEQ ID NO: 157 ATATTGATGATGATATG
cb9	GGGAGACAGAATAACCATCACTTGCCAGGCAACTCAAGACATTGTTAAGAATT SEQ ID NO: 158 TAAACTGGTATCAGCAG
ce9	CTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAAC SEQ ID NO: 159 AGGTAATACGCTTCC
cf9	TTGCAGCAGAAACCAGGAAATCATTTAAGGCTGATCTATCATGGAACCAA SEQ ID NO: 160 CTTGGAAAGATGGAGTTC
ci12	TCGGGAGAAAGTGTCAACCATCATGCCTGGCAAGTCAGACCATTGGTACAT SEQ ID NO: 161 GGTTAGCATGGTATCAG
cj9	CCGGCAAGTCAGGACATTTCATGGTTATTTAAACTTGTTCAGCAGAAACCAG SEQ ID NO: 162 GTGAAACTATTAAACAC
cp9	TTCTCTCACCATCAGCAACCTGGAACCTGAAGATATTGCCACTTACTATTGTCA SEQ ID NO: 163 GCAGTATAGTAAGCTT
cr1	CTAGTCAGAGCATTGTACATAGTAATGGAACACCTATTTAGAAATGGTACCTG SEQ ID NO: 164 CAGAAACCAGGCCAGTC
cs1	CACTCAAGATCAGCACAATAAAGCCTGAGGACTTGGGAATGTATTACTGCTTA SEQ ID NO: 165 CAAGGTACACATCAGCC

TABLE 3-continued

Mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.	
Gene	Sequence
cv1	AGATCAAGCCTCTATCTCTTGCAAGTCTACTAAGAGTCTTCTGAATAGTGATGG SEQ ID NO: 166 ATTCACTTATTTGGAC
cw9	AAATTAGTGGTTACTTAAGCTGGCTTCAGCAGAAACCAGATGGAACATTTAAA SEQ ID NO: 167 CGCCTGATCTACGCCGC
cy9	CAGTCTCTCTTGTGCGGCTAGTCAGGGCATTAGAGGTAATTTAGACTGGTATCA SEQ ID NO: 168 GCAGAAACCAGGTGGA
dv-36	GCAGAAAGCAGAGCAAGTTCCCCGGCTCCTTATCCATAGTGCCTCCACTAGGG SEQ ID NO: 169 CCGTGGTGTCCAGTC
fl12	AGTATTCTCTCAAGATCAGTAGCCTGCATCCTGACGATGTTGCAACGTATTACT SEQ ID NO: 170 GTCAAATGTGTTAAG
gj38c	ACCAACACAAGCCTGGAAAAGTCCCTAGGCTGCTCATACTACACATCTACA SEQ ID NO: 171 TTACAGCCAGGCATCCC
gm33	CTCCTTTCTGTATCTCTAGGAGACAGAGTCACCATTACTTGCAAGGCAAGTGA SEQ ID NO: 172 GGACATATAAATCGG
gn33	CTACTTGTCTGTATCTCTAGGAGGCAGAGTCACCATTACTTGCAAGGCAAGTGA SEQ ID NO: 173 CCACATTAATAATTGG
gr32	CCAGGAAATATTCTAAACTATTGATCTATAAGGCTTCCAACCTGCACACAGGC SEQ ID NO: 174 GTCCCATCAAGGTTTA
he24	TATTGTGATGACGCAGGCTGCATTCTCCAATCCAGTCACTCTTGGAACATCAGC SEQ ID NO: 175 TTCCATCTCTGCAGG
hf24	ATATTGTGATGACTCAGGCTGCACCCCTGTACTCTGCTCACTCCTGGAGAGTCAG SEQ ID NO: 176 TATCCATCTCCTGCAG
hg24	TCTAGTAAGAGTCTCCTATATAAGGATGGGAAGACATACTTGAATTGGTTTCTG SEQ ID NO: 177 CAGAGACCAGGACAAT
if11	TGACTTGCCAGGCAGTCAGGGCACTAGCATTAAATTTAAACTGGTTTCAGCAA SEQ ID NO: 178 AAACCAGGGAAAGCTCC
kb4	AATTGTGCTCACTCAGTCTCCAGCCATCACAGTGCATCTCTGGGGCAAAGG SEQ ID NO: 179 TCACCATCACCTGCAGT
kf4	CCCGGGGAGAAGATCACTATCACCTGCAGTCCAGCTCAAGTATAAGTTCCAA SEQ ID NO: 180 TTACTTGCATTGGTATC
kh4	GCTCAAGTATAAGTTCCAGCAACTTGCACTGGTACCAGCAGAAGTCAGAAACC SEQ ID NO: 181 TCCCCAAACCCTGGAT
kj4	TTACTTGCCTGGTACGAGCAGAAGTCAGGCGCTTCCCCAAACCCTTGATTCA SEQ ID NO: 182 TAGGACATCCAACCTG
kk4	CTCAAGTGTAAAGTTACATGCAGTGGTACCAGCAGAAGTCAGGCACCTCCCCA SEQ ID NO: 183 AAAGATGGATTTATGAC
km4	AGGATCCTCGCCCAAACCCTGGATTTATGACACATCCAACCTGGCTTCTGGATT SEQ ID NO: 184 CCCTGCTCGCTTCAGT
kn4	CCAGCTCAAGTATAAGTTACATGCAGTGGTACCAGCAGAAGCCAGGCACCTCC SEQ ID NO: 185 CCCAAAGATGGATTTA
Kappa	CTTCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGTAGAGACAAAGGTC SEQ ID NO: 186 Constant TGAGACGCCACCACCAG
Lambda1	AGAAACATGCCCAAGTATCCTTGGTGCCTTTTGCCTACCATAGCCCTTCTCTC SEQ ID NO: 187 Constant TACCCTCAAATGCAC
Lambda2	CCGTGTTTCCACCTTCTCTGAGGAGCTCAAGGAAAACAAAGCCACACTGGTG SEQ ID NO: 188 Constant TGTCTGATTCCAACCT

TABLE 3-continued

Mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.	
Gene	Sequence
Lambda3	AATCCCTTCTTTCATTACACAGGTCAGCCCAAGTCCACTCCCAGATCACCAT SEQ ID NO: 189
Constant	GTTTCCACCTTCCCCT
Actin	CGTGCACCGCAAGTGCTTCTAGGCGGACTGTTACTGAGCTGCGTTTTACACCCT SEQ ID NO: 190
Beta	TTCTTTGACAAAACCT

[0031]

TABLE 4

Additional human light chain V gene oligonucleotides. The complements of these sequences may also be used.	
Sequence Name	Secondary Sequence
>A1_134	AGGCCAATCTCCAAGGCGCTAATTTATAAGGTTTCTAACTGGGACTCTGG SEQ ID NO: 191 GGTCCCAGACAGATTCAGC
>A11_93	AGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCTGGCGCCAGGCTCCTC SEQ ID NO: 192 ATCTATGATGCATCCAGCA
>A14_28	TCCTCTCTGTGACTCCAGGGGAGAAAGTCACCATCACCTGCCAGGCCAGTG SEQ ID NO: 193 AAGGCATGGCAACTACTT
>A17_134	AGGCCAATCTCCAAGGCGCTAATTTATAAGGTTTCTAACCGGACTCTGG SEQ ID NO: 194 GGTCCCAGACAGATTCAGC
>A18b_109	CTATTTGTATTGGTACCTGCAGAAGCCAGGCCAGTCTCCACAGCTCCTAAT SEQ ID NO: 195 CTATGAAGTTTCCAGCCGG
>A19_159	TATTTGGGTTCTAATCGGGCTCCGGGTCCTGACAGGTTTCAGTGGCAGT SEQ ID NO: 196 GGATCAGGCACAGATTTTA
>A2_109	ATTTGTATTGGTACCTGCAGAAGCCAGGCCAGCTCCACAGCTCCTGATCT SEQ ID NO: 197 ATGAAGTTTCCAACCGGTT
>A20_123	AAAGTTCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAATCAGGGTCC SEQ ID NO: 198 CCATCTCGGTTTCAGTGGCA
>A23_143	TCCAAGACTCCTAATTTATAAGATTTCTAACCGGTTCTCTGGGGTCCCAGA SEQ ID NO: 199 CAGATTCAGTGGCAGTGGG
>A26_65	CTGCCGGCCAGTCAGAGCATGGTAGTACTTACACTGGTACCAGCAGA SEQ ID NO: 200 AACCAGATCAGTCTCCAAAG
>A27_1	AAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAA SEQ ID NO: 201 GAGCCACCCTCTCCTGCAG
>A30_85	TTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGAAAGCCCTAAG SEQ ID NO: 202 CGCCTGATCTATGCTGCATC
>A5_101	ATACACCTATTGTATTGGTTTCTGCAGAAAGCCAGGCCAGTCTCCACACT SEQ ID NO: 203 CCTGATCTATGAAGTTTCC
>A7_222	GATTTCACACTGAAAATCAGCAGGTTGGAAGCTGAGGATGTCGGGGTTTA SEQ ID NO: 204 TTACTGCACGCAAGCTACAC
>B2_214	CCCTCACAATTAATAACATAGAATCTGAGGATGCTGCATATTACTTCTGTC SEQ ID NO: 205 TACAACATGATAATTTCCC
>B3_27	TCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAGTCCAGC SEQ ID NO: 206 CAGAGTGTTTTATACAGCT
>L1_71	GGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACCAG SEQ ID NO: 207 GGAAAGCCCTAAGTCCCTG

TABLE 4-continued

Additional human light chain V gene oligonucleotides. The complements of these sequences may also be used.		
Sequence Name	Secondary Sequence	
>L10_92	CAGTACTTAACTGGTATCAGCAGAAACCTGGCCAGGCGCCAGGCTCCT CATCTATGGTGCATCCACC	SEQ ID NO: 208
>L11_217	TCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTAC AAGATTACAATTACCCTCC	SEQ ID NO: 209
>L12_47	AGACAGAGTCACCATCACTTGCCGGCCAGTCAGAGTATTAGTAGCTGGTT GGCCTGGTATCAGCAGAAA	SEQ ID NO: 210
>L14_68	TCGGGCGAGGCGAGGATTAGCAATTATTTAGCCTGGTTTCAGCAGAAACC AGGAAAGTCCCTAAGCAC	SEQ ID NO: 211
>L15_92	CTGGTTAGCCTGGTATCAGCAGAAACCAGAAAAGCCCTAAGTCCCTGA TCTATGCTGCATCCAGTTTG	SEQ ID NO: 212
>L16_217	TCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCACTTATTACTGTCCAGC AGTATAATAACTGACCTCC	SEQ ID NO: 213
>L18_216	CTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAA CAGTTAATAATTACCCTC	SEQ ID NO: 214
>L19_206	AGATTTCACTCTCACTATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTA CTATTGTCAACAGGCTAAC	SEQ ID NO: 215
>L2_217	TCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCACTTATTACTGTCCAGC AGTATAATAACTGACCTCC	SEQ ID NO: 216
>L20_193	GTGGGCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAA GATTTTGCACTTATTACTG	SEQ ID NO: 217
>L22_113	GAAACCAGGGAATCCCTAAGCTCTTCTCTATGATGCAAAAGATTTGCA CCCTGGGCTCATCGAGG	SEQ ID NO: 218
>L23_104	GTATCAGCAAAAACCAGCAAAAGCCCTAAGCTCTTCACTATTATGCATC CAGTTTGCAAGTGGGGTC	SEQ ID NO: 219
>L24_24	TCCTTACTCTCTGCATCTACAGGAGACAGAGTCACCATCAGTTGTCCGATG AGTCAGGCATTAGCAGTT	SEQ ID NO: 220
>L25_92	CAGTACTTATFCTGGTACCAGCAGAAACCTGGGCGGCTCCAGGCTCCT CATCTATGGTGCATCCACC	SEQ ID NO: 221
>L4/18a_216	CTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAA CAGTTAATAGTTACCCTC	SEQ ID NO: 222
>L5_196	GATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATT TTGCAACTTACTATTGTCA	SEQ ID NO: 223
>L6_49	AAAGAGCCACCTCTCCCTGCAGGGCCAGTCAGAGTGTAGCAGCTACTTAG CCTGGTACCAACAGAAAACC	SEQ ID NO: 224
>L8_215	TCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCA ACAGCTTAATAGTTACCCT	SEQ ID NO: 225
>L9_28	CATTCTCTGCATCTACAGGAGACAGAGTCACCATCACTTGTCCGGCGAGTC AGGGTATTAGCAGTTATTT	SEQ ID NO: 226
>O1_159	ATCTATACGCTTTCTATCGGGCCTCTGGAGTCCAGACAGGTTCACTGGC AGTGGGTCAGGCACTGATT	SEQ ID NO: 227
>O2_215	TCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCA ACAGAGTTACAGTACCCTC	SEQ ID NO: 228
>O4_217	TCACTATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACGGTCAAC GGACTTACAATGCCCTCC	SEQ ID NO: 229
>O8_145	ACGATGCATCCAATTTGGAACAGGGTCCCATCAAGGTTCACTGGAAGT GGATCTGGGACAGATTTTAC	SEQ ID NO: 230

TABLE 4-continued

Additional human light chain V gene oligonucleotides. The complements of these sequences may also be used.		
Sequence Name	Secondary Sequence	
>V1-11_121	CAGGAAAGGCTCCCAAACCTCATCTATTATGATGATCTGCTGCCCTCAG GGTCTCTGACCGATTCTC	SEQ ID NO: 231
>V1-13_228	ATCACTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCCAGTCCAT GACAGCAGCCTGAGTGGTT	SEQ ID NO: 232
>V1-16_51	GTCACCATCTCTTGTCTGGAAGCAGCTCCAACATCGGAAGTAATACTGTA AACTGGTACCAGCAGCTCC	SEQ ID NO: 233
>V1-17_93	AATTATGTATACTGGTACCAGCAGCTCCCAGGAACGGCCCCAAACTCCTC ATCTATAGTAATAATCAGC	SEQ ID NO: 234
>V1-18_226	CCATCACTGGACTCCAGTCTGAGGATGAGGCTGATTATTACTGCAAAGCAT GGGATAACAGGCTGAATGC	SEQ ID NO: 235
>V1-19_225	ATCACCGGACTCCAGACTGGGGACGAGGCCGATTATTACTGCGGAACATG GGATAGCAGCCTGAGTGCTG	SEQ ID NO: 236
>V1-2_227	CGTCTCTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCAGCTCATA TGCAGGCAGCAACAATTTTC	SEQ ID NO: 237
>V1-20_91	ACCAAGGAGCAGCTTGGCTGCAGCAGCACCAGGGCCACCCTGCCAAACTC CTATCCTACAGGAATAACAA	SEQ ID NO: 238
>V1-22_36	TCTCCGGGGAAGACGGTAACCATCTCCTGCACCCGAGCAGTGGCAGCATT GCCAGCAACTATGTGCAGT	SEQ ID NO: 239
>V1-3_227	CATCTCTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCTGCTCATA TGCAGGCAGCTACACTTTTC	SEQ ID NO: 240
>V1-4_143	CATGATTTATGAGGTCAGTAATCGGCCCTCAGGGGTTTCTAATCGTCTCTCT GGTCCAAGTCTGGCAAC	SEQ ID NO: 241
>V1-5_85	TTGGTAGTTATAACCGTGTCTCCTGGTACCAGCAGCCCCAGGCACAGCCC CCAAACTCATGATTTATGA	SEQ ID NO: 242
>V1-7_227	AATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCTGCTCATA TGCAGGTAGTAGCACTTTTC	SEQ ID NO: 243
>V1-9_83	CGTTGGGGATTATGATCATGTCTTCTGGTACCAAAGCGTCTCAGCACTAC CTCCAGACTCCTGATTTAC	SEQ ID NO: 244
>V2-1_30	TCCGTGTCCCAGGACAGACAGCCAGCATCACCTGCTCTGGAGATAAATTG GGGATAAATATGCTTGCT	SEQ ID NO: 245
>V2-11_84	AAAAAATATGCTTATTTGGTACCAGCAGAAGCCAGGCCAGTTCCCTGTGCTG GTGATATATAAGACAGCG	SEQ ID NO: 246
>V2-13_44	ACAGACAGTCAAGGATCAGTCCAAAGGAGACAGCCTCAGAAGCTATTATG CAAGCTGGTACCAGCAGAAG	SEQ ID NO: 247
>V2-14_218	CATCAGCAGGTCGAAGCCGGGATGAGGCCGACTATTACTGTCAGGTGT GGGATAGTAGTAGTATCAT	SEQ ID NO: 248
>V2-15_125	CCCTGAGTTGGTGATATACGAAGATAGTGAGCGGTACCCTGGAATCCCTGA ACGATTCTCTGGGTCCACC	SEQ ID NO: 249
>V2-17_204	ACAGTCACGTTGACCATCAGTGGAGTCCAGGCAGAAGATGAGGCTGACTA TTACTGTCAATCAGCAGACA	SEQ ID NO: 250
>V2-19_211	CCTTGACCATCAGCGGGGCCAGGTTGAGGATGAGGCTGACTATTACTGTT ACTCTGCGGCTGACAACAA	SEQ ID NO: 251
>V2-6_215	GACCATCAGCAGAGCCCCAAGCCGGGATGAGGCTGACTATTACTGTCAGG TGTGGGACAGCAGCACTGCA	SEQ ID NO: 252
>V2-7_220	TCAGTGGGGCCAGGTGGAGGATGAAGCTGACTACTACTGTTACTCAACA GACAGCAGTGGTAATCATAG	SEQ ID NO: 253

TABLE 4-continued

Additional human light chain V gene oligonucleotides. The complements of these sequences may also be used.		
Sequence Name	Secondary Sequence	
>V2-8_189	TCCAACCCAGGGAACACCCGCCACCCTAACCATCAGCAGGATCGAGGCTGG GGATGAGGCTGACTATTACT	SEQ ID NO: 254
>V3-2_224	GACACTGTCAGGTGTGCAGCCTGAGGACGAGGCTGAGTATTACTGCCTGCT CTACTATGGTGGTCTCAG	SEQ ID NO: 255
>V3-3_95	TCATTATCCCTACTGGTTCCAGCAGAAGCCTGGCCAAGCCCCCAGGACACT GATTTATGATACAAGCAAC	SEQ ID NO: 256
>V3-4_209	GAACAAAGCTGCCCTCACCATCACGGGGCCAGGAGATGATGAATCTG ATTATTACTGTGTCTGTAT	SEQ ID NO: 257
>V4-1_20	ACCTTCCTCCTCCGCATCTCCTGGAGAATCCGCCAGACTCACCTGCACCTT GCCAGTGACATCAATGTT	SEQ ID NO: 258
>V4-2_110	GTACCAGCAGAAGCCAGGGAGTCTCCCCAGTATCTCCTGAGGTACAAAT CAGACTCAGATAAGCAGCAG	SEQ ID NO: 259
>V4-3_110	GTACCAGCAGAAGCCAGAGAGCCCTCCCGGTATCTCCTGAGCTACTACTC AGACTCAAGTAAGCATCAG	SEQ ID NO: 260
>V4-4_66	ATGCTGAGCAGTGGCTTCAGTGTGGGGACTTCTGGATAAGGTGGTACCAA CAAAGCCAGGGAACCCCTC	SEQ ID NO: 261
>V4-6_182	ACCTGGGGTCCCCAGTCGAGTCTCTGGCTCCAAGGAGACCTCAAGTAACAC AGCGTTTTGTCTCATCTCT	SEQ ID NO: 262
>V5-1_77	TGAGCACAGCACCTACACCATCGAATGGTATCAACAGAGACCAGGGAGGT CCCCCAGTATATAATGAAG	SEQ ID NO: 263
>V5-2_237	ATCAAGAACATCCAGGAAGAAGATGAGAGTACTACCCTGTGGGGCAGA CCATGGCAGTGGGAGCAACT	SEQ ID NO: 264
>V5-4_117	CCAGGGAAGGCCCTCGGTACTTGATGAAGCTTGAAGGTAGTGAAGCTA CAACAAGGGGAGGGGAGTTC	SEQ ID NO: 265
>V5-6_120	GAGAAGGGCCCTCGGTACTTGATGAAGCTTAACAGTGTGGCAGCCACAG CAAGGGGACGGGATCCCTG	SEQ ID NO: 266

[0032]

TABLE 5

Additional mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
	Secondary Sequence	
12-38-65	CATGTCGAGCAAGTGAGAACATTTACTACAGTTTAGCATGGTATCAGCAGAAGC AAGGAAATCTCC	SEQ ID NO: 267
12-41-86	TTCAACAATTATTTAGCATGGTATCAGCAGAAACAGGGAAAATCTCCTCAGGTCCT GGTCTATAATGC	SEQ ID NO: 268
12-44-70	CGAGCAAGTGAGAATATTTACAGTTATTTAGCATGGTATCAGCAGAAACAGGGA AAATCTCCTCAGC	SEQ ID NO: 269
12-46-70	CGAGCAAGTGAGAATATTTACAGTAATTTAGCATGGTATCAGCAGAAACAGGGA AAATCTCCTCAGC	SEQ ID NO: 270
19-13-103	TGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTACTCGGCATCC AATCGGTACTACTG	SEQ ID NO: 271
19-14-197	GATCTGGGACAGATTTCACTCTCACCATTAGCAATGTGCAATCTGAAGACCTGG CAGATTATTTCTG	SEQ ID NO: 272

TABLE 5-continued

Additional mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Secondary Sequence		
19-15-217	CTCACCATCAGCAATGTGCAGTCTGAAGACTTGGCAGAGTATTTCTGTGCAAT ATAACAGCTATC	SEQ ID NO: 273
19-17-215	CTTTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTGCA ACATTATAGTAC	SEQ ID NO: 274
19-20-69	CAAGGCCAGTGAGAATGTGGTACTTATGTATCCTGGTATCAACAGAAACCAGA GCAGTCTCCTAAA	SEQ ID NO: 275
19-23-206	CAGATTTCACTCTCACCATTAGCAATGTGCAGTCTGAAGACTTGGCAGATTATTT CTGTGCAATATAG	SEQ ID NO: 276
19-25-209	ATTATACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCACTTTATTACTG TCAGCAACATTATA	SEQ ID NO: 277
19-29-69	CAAGGCCAGTGAGAATGTGGTACTTATGTATCCTGGTATCAACAGAAACCAGA GCAGTCTCCTAAA	SEQ ID NO: 278
19-32-124	CAGTCTCTAAACTGCTGATATACTATGCATCCAATCGCTACACTGGAGTCCCTG ATCGCTTCACTG	SEQ ID NO: 279
21-1-117	GTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAA CGTAGAATCTGGG	SEQ ID NO: 280
21-10-210	GTCTAGGACAGACTTCACCCTCACCATTGATCCTGTGGAGGCTGATGCTGCA ACCTATTACTGT	SEQ ID NO: 281
21-12-117	GTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATCTTGCATCCAA CCTAGAATCTGGG	SEQ ID NO: 282
21-2-229	CTCAACATCCATCCTATGGAGGAGGATGATACTGCAATGTATTTCTGTGCAAA AGTAAGGAGGTTT	SEQ ID NO: 283
21-3-66	CTGCAGAGCCAGCCAGAGTGTGATTATAATGGAATTAGTTATATGCACTGGTT CCAACAGAAACCA	SEQ ID NO: 284
21-4-117	GTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAA TCTAGAATCTGGG	SEQ ID NO: 285
21-5-196	TTCAGTGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATTAATCCTGTGGAG GCTGATGATGTTG	SEQ ID NO: 286
21-7-229	CTCAACATCCATCCTGTGGAGGAGGATGATACTGCAACATATTACTGTGCAAC AGTTGGGAGATTC	SEQ ID NO: 287
21-9-212	CTGAGTCACTTCACTCTCACCATCGATCCTGTGGAGGAAGATGATGCTGCAA TGTATTACTGTAT	SEQ ID NO: 288
22-33-217	TCTGGGACAGATTTCACCTCTGACCATCAGCAGTGTACAGGTTGAAGACCTCACA CATTATTACTGTG	SEQ ID NO: 289
23-37-81	GAGTATTTACAAGAACCCTACTGGTATCAACAGAAATCACATCGGTCTCCAAG GCTTCTCATCAAGTATG	SEQ ID NO: 290
23-39-202	GGTTCAGATTTCACTCTCAGTATCAACAGTGTGGAACCTGAAGATGTTGGAGTG TATTACTGTCAA	SEQ ID NO: 291
23-43-195	TGGATCAGGGACAGATTTCACTCTCAGTATCAACAGTGTGGAGACTGAAGATTT TGGAATGTATTCT	SEQ ID NO: 292
23-45-76	AGTCAAAGTATTAGCAACTACCTACACTGGTATCAACAAAAATCACATGAGTCT CCAAGGCTTCTCA	SEQ ID NO: 293
23-48-184	TTTAGTGGCAGTGGATCAGGACAGATTTTACTCTTAGCATCAACAGTGTGGAG TCTGAAGATATTG	SEQ ID NO: 294
4-50-103	TACCAGCAGAAGTCAGATGCCTCCCCCAAATATGGATTTATTACACATCCAAC CTGGCTCCTGGAG	SEQ ID NO: 295
4-51-207	GATCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAAATGATGCAACTTAT TACTGCCAGCAG	SEQ ID NO: 296

TABLE 5-continued

Additional mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Secondary Sequence		
4-57-210	CTCTTACTCTCTCACAATCAGCAGTGTGGAGGCTGAAGATGCTGCCACTTATTAC TGCCAGCAGTAC	SEQ ID NO: 297
8-16-170	CATCTGATAGGTACTCTGGAGTCCCTGATCGTTTCATAGGCAGTGGATCTGTGAC AGATTTCACTCT	SEQ ID NO: 298
8-19	GAGAGAAGGTCACATATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAA ATCAAAAAGAACTA	SEQ ID NO: 299
8-21	GAAGGTCACATATGAGCTGCAAAATCCAGTCAGAGTCTGCTCAACAGTAGAACCCG AAGAAGTACTTG	SEQ ID NO: 300
8-24	GACAGAAGGTCACATATGAGCTGCAAGTCCAGTCAGAGCCTTTTAAATAGTAGCA ATCAAAAAGAACTA	SEQ ID NO: 301
8-27	GCAGGAGAAAAGGTCACATATGAGCTGTAAGTCCAGTCAAAGTGTTTTATACAGT TCAAATCAGAAGAAC	SEQ ID NO: 302
8-28	GAGAGAAGGTCACATATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAA ATCAAAAAGAACTA	SEQ ID NO: 303
8-30	TTGGAGAGAAGGTTACTATGAGCTGCAAGTCCAGTCAGAGCCTTTTATATAGTA GCAATCAAAAAGAACTACTT	SEQ ID NO: 304
8-34-143	GATCTCTAAAATGCTGATAATTTGGGCATCCACTAGGGTATCTGGAGTCCCTGA TCGCTTCATAGG	SEQ ID NO: 305
RF-40	TCTCTGGAGAAACCATTACTATTAATTGCAGGGCAAGTAAGAGCATTAGCAAA TATTTAGCCTGGTATCAAG	SEQ ID NO: 306
aa4-1	CAAATGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAG GTCACCATATCCT	SEQ ID NO: 307
ac4-197	CTGGAAACTCTTACTCTCTCACGATCAGCAGCATGGAGGCTGAAGATGTTGCCA CTTATTACTGTTT	SEQ ID NO: 308
ad4-26	CAATCATGTCTGCATCTCCTGGGAGAAAGGTCACCATGACCTGCAGTCCAGAT CAAGTGTAAGTTC	SEQ ID NO: 309
ae4-1	CAAATGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCTGGGAGAAGG TCACCTTGACCT	SEQ ID NO: 310
af4-120	CACCTCTCCAAACTCTTGATTTATAGCACATCCAACCTGGCTTCTGGAGTCCCT TCTCGCTTCAGT	SEQ ID NO: 311
ag4-128	CTTCTACCAAAATCTGGATTTATAGGACATCCAACCTGGCTTCTGAGTCCCAGC TCCCTTCAGTGG	SEQ ID NO: 312
ah4-125	GATCCTCCCCAAACTCTGGATTTATAGCATATCCAACCTGGCTTCTGGAGTCCC AGCTCGCTTCCAG	SEQ ID NO: 313
ai4-1	CAAATGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCTAGGGGAACGGG TCACCATGACCT	SEQ ID NO: 314
aj4-119	GATCCTCCCCAAACTCTGGATTTATAGCATATCCAACCTGGCTTCTGGAGTCCC TGCTCGCTTCCAG	SEQ ID NO: 315
al4-133	CTCTGGATTTATTTAACAATCAACTTGGCTTCTGGAGTCCCTGCTCGCTTCCAGTGG CAGTGGGCTCTG	SEQ ID NO: 316
am4-212	CTCTCACAATCAGCAGAGTGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGC AGTGGAGTAGTAA	SEQ ID NO: 317
an4-203	CATCTTTCTCTTTCACAATCAACAGCATGGAGGCTGAAGATGTTGCCACTTATTA CTGTCAGCAAAG	SEQ ID NO: 318
ap4-80	CAAGTGTAAGTTACATGCACCTGGTTCCAGCAGAAGCCAGGCACCTTCTCCAAAC TCTGGATTTATAG	SEQ ID NO: 319

TABLE 5-continued

Additional mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
	Secondary Sequence	
aq4-38	CATCTCGAGGGGAGAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAGTT ACATGTACTGGTA	SEQ ID NO: 320
ar4-180	CTTCAGTGGCAGTGGATCTGGGACCTCTTATCTCTCACAATCAGCAGCATGGAG GCTGAAGATGCT	SEQ ID NO: 321
at4-38	CATCTCCAGGGGAGAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAGTT ACATGTACTGGTA	SEQ ID NO: 322
ay4-44	GAGGGGAGAAGGTCACCATCACCTGCCGTGCCAGCTCAAGTATAAGTTCCAATT ACTTACACTGGTA	SEQ ID NO: 323
ba9-195	TGGATCTGGGCAAGATTATTCTCTCACCATCAGCAGCCTGGAGTATGAAGATAT GGGAATTTATTATT	SEQ ID NO: 324
bb1-60	CATCTCTTGCAGATCTAGTCAGAGCCTTGTCACACAGTAATGGAAACACCTATTTA CATTGGTACCTG	SEQ ID NO: 325
bb1.1-59	CCATCTCTTGCAGATCTAGTCAGAGCCTTGTCACACAGTAATGGAAACACCTATTT ATATTGGTACCTG	SEQ ID NO: 326
bd2-85	CTCTTAGATAGTGTGGAAAGACATATTTGAATTGGTTGTTACAGAGGCCAGGC CAGTCTCCAAAGC	SEQ ID NO: 327
bi2-172	AAACTGGACCCTGGCATCCCTGACAGGTTAGTGGCAGTGGATCAGAAACAGAT TTTACACTTAAAAAT	SEQ ID NO: 328
bj2-108	CTATTTGAATTGGTTATTACAGAGGCCAGGCCAGTCTCCAAGCGCCTAATCTAT CTGGTGTCTAAA	SEQ ID NO: 329
b11-57	CTCCATCTCTTGCAGGCTAGTCAGAGCCTTGAAACAGTAATGGAAACACCTA TTTGAAGTGGTAC	SEQ ID NO: 330
bt20-123	GGAACCTCCTAAGCTCCTTATTTCAGAAGCAATACTCTTCGTCCTGGAGTCCCA TCCCGATTCTCC	SEQ ID NO: 331
bv9-81	GGACATGGTAGTAGCTTAACTGGCTTCAGCAGGAACCAGATGGAACATTTAA ACGCCTGATCTAC	SEQ ID NO: 332
bw20-123	GGAACCTCCTAAGCTCCTTATTTCAGAAGCAATACTCTTCGTCCTGGAGTCCCA TCCCGATTCTCC	SEQ ID NO: 333
cb9-42	TCTGGGAGACAGAATAACCATCACTTGCCAGGCAACTCAAGACATTGTTAAGAA TTTAAACTGGTAT	SEQ ID NO: 334
ce9-184	TTCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGC AAGAAGATATTG	SEQ ID NO: 335
cf9-109	CAGCAGAAACCAGGAAATCATTTAAGGCCTGATCTATCATGGAACCAACTTG GAAGATGGAGTTC	SEQ ID NO: 336
ci12-81	GACCATTGGTACATGGTTAGCATGGTATCAGCAGAAACCAGGAAATCTCCTCA GCTCCTGATTTAT	SEQ ID NO: 337
cj9	ACCTGATCTATGAAACATCCAATTTAGATTCTGGTGTCCAAAAAGGTTCAAGTG CAGTAGGCTCTGG	SEQ ID NO: 338
cp9	TTATCTCTCACCATCAGCAACCTGGAACCTGAAGATATTGCCACTTACTATTGT CAGCAGTATAGT	SEQ ID NO: 339
cr1	GGAGATCAAGCCTCCATCTCTTGAGATCTAGTCAGAGCATTGTACATAGTAAT GGAACACCTATTTAGAAT	SEQ ID NO: 340
cs1	GATFTCACACTCAAGATCAGCACAATAAAGCCTGAGGACTTGGGAATGTATTAC TGCTTACAAGGTA	SEQ ID NO: 341
cv1	CTCAAGATCAGCAGAGTGGAGGCTGAGGATTTGGGAGTTTATTATTGCTTCCAG AGTAACATCTTC	SEQ ID NO: 342
cw9	GGAAATTAGTGGTTACTTAAAGCTGGCTTCAGCAGAAACCAGATGGAACATTTAA ACGCCTGATCTAC	SEQ ID NO: 343

TABLE 5-continued

Additional mouse light chain V gene selected oligonucleotides. The complements of these sequences may also be used.		
Secondary Sequence		
cy9	CTAGTCAGGGCATTAGAGGTAATTTAGACTGGTATCAGCAGAAACCAGGTGGAA CTATTAAACTCCTG	SEQ ID NO: 344
dv-36	GAAACAACACAGGCTCCAGCTTCTCTGAGTTTTTCTCTTGGTGAACAGCAACAC TGTCATGCAGGTC	SEQ ID NO: 345
fl12	CAAGTGAGAATATTTACGGTGCTTTAAATTGGTATCAGCGGAAACAGGAAAAT CTCCTCAGCTCCT	SEQ ID NO: 346
gj38c	CTGCTCATAcATTACACATCTACATTACAGCCAGGCATCCCATCAAGGTTcAGTG GAAGTGGGTCTG	SEQ ID NO: 347
gm33	GTTCCTTCAAGATTCAGTGGCAGTGGATCTGAAAGGATTACACTCTCAGCATTa CCAGTCTTCAGa	SEQ ID NO: 348
gn33	GACATCCAGATGACACAATCTTCATCCTACTTGCTGTATCTCTAGGAGGCAGAG TCACCATTACTT	SEQ ID NO: 349
gr32	GGAAATATTCTAAACTATTGATCTATAAGGCTTCCAAC TTGCACACAGGCGTCC CATCAAGGTTTA	SEQ ID NO: 350
he24	GATATTGTGATGACGCAGGCTGCATTTCCAATCCAGTCACTCTTGGAAACATCAG CTTCCATCTCCT	SEQ ID NO: 351
hf24	CTGAGAATCAGTAGAGTGGAGGCTGAGGATGTGGGTGTTTATTACTGTATGCAA CATCTAGAATATCC	SEQ ID NO: 352
hg24	CTGGAAATCAGTAGAGTGAAGGCTGAGGATGTGGGTGTATTACTGTGAACAA CTTGTAGAGTATC	SEQ ID NO: 353
if11	TCTCACCATCAGCAGCCTGGAGGATGAAGATATGGCAACTTATTTCTGTCTACAG CATAGTTATCTC	SEQ ID NO: 354
kb4	CATGGATTTATGAAATATCCAAACTGGCTTCTGGAGTCCAGCTCGCTTCAGTGG CAGTGGGTCTGG	SEQ ID NO: 355
kf4	CAATTACTTGcATTGGTATCAGCAGAGCCAGGATTTCCcCTAAACTCTTGATT TATAGGACATCC	SEQ ID NO: 356
kh4	CTTCTGGAGTCCCTGTTCGCTTCAGTGGCAGTGGATCTGGGACCTCTTATTCTCTC ACAATCAGCAG	SEQ ID NO: 357
kj4	GGTCTGGGACCTCTTACTCTCTCACAATCAGCAGCGTGGAGGCTGAAGATGATG CAACTTATTACTG	SEQ ID NO: 358
kk4	CCCAAAAGATGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCT TCAGTGGCAGTG	SEQ ID NO: 359
km4	CAAATTCTTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAG GTCACCATGACCT	SEQ ID NO: 360
kn4	CCCAAAAGATGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCT TCAGTGGCAGTG	SEQ ID NO: 361
ko4	CTTCAGTGGCAGTGGATCTGGGACCTCTTATTCTCTCACAATCAGCAGCATGGAG GCTGAAGATGCT	SEQ ID NO: 362
VL1	AAGTACTGGGGCTGTTACAAC TAGTAAC TATGCCAACTGGGTCCAAGAAAACC AGATCATTTTATTCT	SEQ ID NO: 363
VL2	GTA CTGGGGCTGTTACAAC TAGTAAC TATGCCAACTGGGTCCAAGAAAACCAG ATCATTATTACT	SEQ ID NO: 364
VLx	TTAGCATTTCCAACATCCAGCCTGAAGATGAAGCAATATACATCTGTGGTGTGG GTGATACAATTAA	SEQ ID NO: 365

[0033] One of skill in the art appreciates that whether an oligonucleotide is “capable of hybridizing” to another polynucleotide depends in part on the stringency of the conditions used during hybridization. As used herein “capable of hybridizing” to a polynucleotide encoding the light chain variable region, or the complement thereof, is one that hybridizes under high stringency conditions. In the Examples, high stringency hybridization was carried out at 45° C. in a buffer containing 50% formamide, 5×SSC, 0.1% SDS and 0.1 mg/mL BSA. After hybridization, the microarrays were washed in 2×SSC, 0.1% SDS at 42° C. for 5 minutes, two times in 1×SSC at room temperature, two times in 0.1×SSC, and in water for 30 seconds. One of skill in the art would appreciate that the hybridization and washing conditions can be altered while maintaining high stringency conditions.

[0034] Oligonucleotides corresponding to the sequences in Table 2 and Table 3 were generated and printed onto a glass slide to form the microarray used in the Examples. One of skill in the art would appreciate that a microarray having a subset of the oligonucleotides of Tables 2 and 3 may also be useful. For example, a microarray comprising a subset of oligonucleotides capable of hybridizing to a polynucleotide comprising a sequence encoding at least a portion of a light chain variable region that is associated with a disease, or a complement thereof, may be used in the methods of the invention. The subset of oligonucleotides capable of hybridizing to the light chain variable regions associated with a systemic autoimmune disease, such as the light chain variable regions listed in Table 1, may also be useful in the methods of the invention. One of skill in the art would also appreciate that two or more oligonucleotides capable of hybridizing to a single light chain variable gene could be used in the microarray. Use of multiple oligonucleotides specific for the same gene improves resolution and minimizes problems with cross-hybridization.

[0035] In addition to the oligonucleotides capable of hybridizing to the light chain variable regions, or complements thereof, appropriate quality control reporter oligonucleotides may be included in the microarrays of the present invention. Tables 2 and 3 include several oligonucleotides that were used as controls in the Examples. These include oligonucleotides capable of hybridizing to polynucleotides encoding beta actin, CD19, CD20, the kappa constant region and several lambda constant regions. The controls chosen for use in the Examples are not limiting. One of skill in the art could design control oligonucleotides from a wide variety of cellular genes.

[0036] Each oligonucleotide species used is immobilized at a distinct location or domain on a substantially planar solid surface of a substrate to form a microarray. Any suitable substrate may be used, including, but not limited to, glass, silicon, nitrocellulose, paper or other solid surface materials. The oligonucleotide species can be RNA or DNA. The oligonucleotide species can be immobilized by depositing or synthesizing oligonucleotides at specific locations on the microarray by methods known to those of skill in the art. Generally each oligonucleotide species is present in replicates on the microarray. Alternatively, pools of multiple oligonucleotide species could be used. In the Examples, each oligonucleotide species was printed either six times or ten times in distinct locations to serve as an internal control for even hybridization of the target polynucleotides to the

slide. The replicate oligonucleotide species can be printed near each other, in a set pattern or randomly on the microarray. This generates a microarray chip that serves as a platform for identification and quantification of light chain variable region usage.

[0037] In the Examples, the microarray was used to detect the expression of light chain variable genes in B cells. However, the microarrays could also be used to detect light chain variable gene expression in plasma cells or plasmablasts. The cells may be harvested from any source, as long as the cell sample contains B cells. Peripheral blood is one source for obtaining cells from the subject. Cells may also be harvested from a body fluid of the subject, including, but not limited to synovial fluid, cerebrospinal fluid, lymph, bronchioalveolar lavage fluid, gastrointestinal secretions, saliva, urine, and tears. The cells may also be derived from a tissue of the individual, e.g., by performing a tissue biopsy on tissues, including, but not limited to, the spleen and lymph nodes. When assaying for a particular disease condition the selection of appropriate cell sources will be apparent to those of ordinary skill in the art. For example, to assay for autoimmune disorders affecting the joints (e.g., rheumatoid arthritis), synovial fluid is a suitable source of cells. In a patient with multiple sclerosis, cerebral spinal fluid is a suitable source of cells. In the Examples, the B cells were harvested from cerebral spinal fluid and peripheral blood.

[0038] Fluorescent activated cell sorting (FACS) was used in the Examples to harvest and select B cells by expression of specific cell surface markers, namely CD19 and CD20, and lack of expression of other markers that are indicative of plasma cells, memory B cells and plasmablasts, namely CD138, CD27 and CD38. One of skill in the art will appreciate that other methods of sorting cells may be used, including, but not limited to, magnetic cell sorting, and density gradient centrifugation.

[0039] In the Examples, about 100 of the relevant B cells were pooled as a sample. One of skill in the art appreciates that the number of B cells used can be as few as one or as many as millions. Use of about 100 B cells produced a representative sample of the B cell light chain variable repertoire with little risk of contamination by plasma cells and required only a minimal level of amplification for detection in the microarray.

[0040] Contamination of the B cell samples by plasma cells is a concern because the concentration of light chain mRNA in plasma cells is several thousand fold higher than that of B cells. Contamination by a single plasma cell significantly biases the results of the microarray experiment. The FACS protocol used in the Examples was developed to minimize the chance of plasma cell contamination, but any suitable method of separating plasma cells from the B cells could be used. To reduce plasma cell contamination, after the B cells were sorted and RNA extracted, each sample was tested for the presence of plasma cells using RT-PCR to rule out plasma cell contamination. Importantly, this RT-PCR procedure was optimized using a single cell RT-PCR approach to detect even a single plasma cell in a sample of 100 cells. Samples with detectable plasma cell contamination were not used.

[0041] RNA may be harvested from the B cells by any suitable method. In the examples, sufficient amounts of

nucleic acid for downstream applications was generated from only 100 cells by amplifying the target nucleic acid using an established antisense RNA (aRNA) amplification protocol. Alternatively, cDNA or amplified cDNA could be generated and amplified using any suitable method.

[0042] The resulting target polynucleotides were then labeled with a marker. In the Examples, a fluorescent marker was added to the target polynucleotides. Amplified target polynucleotides can be labeled by any suitable method. For example, labeled nucleotides such as biotinylated UTP or CTP can be incorporated during in vitro transcription. Labeling target molecules may occur after the amplification reaction e.g., by enzymatically modifying the 5' end of the amplified nucleic acids. The label may be any label known to those of skill in the art, suitably the label is a fluorescent label, a radioactive label, or a luminescent label.

[0043] The labeled target polynucleotides are then contacted with the microarray under suitable hybridization conditions. Hybridization buffers and conditions may be altered to increase or decrease the stringency of the conditions as is well-known to those of skill in the art. After hybridization and washing, the microarray was analyzed for presence of bound target polynucleotide by assessing the presence of the label using a commercially available microarray scanner, such as the Axon GenePix 4000B produced by Molecular Devices or another comparable microarray scanner. Commercially available computer programs may be used to analyze the data.

[0044] Several methods are also provided for using the microarray described herein. The microarray may be used to identify light chain variable genes associated with a particular disease by comparing the light chain variable gene usage in subjects with a particular disease to subjects that do not have the disease. Such an analysis may allow identification of light chain variable genes whose expression correlates with the disease in subjects. Diseases that may correlate to particular light chain variable gene usage include, but are not limited to, systemic autoimmune diseases, cancer, especially B cell cancers, such as multiple myeloma, and immunodeficiency diseases. Systemic autoimmune diseases include, but are not limited to, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, scleroderma, Sjogren's syndrome, amyloidosis, psoriasis, mixed connective tissue disease, polymyositis, dermatomyositis, thrombocytopenia, Wegener's granulomatosis, and autoimmune nephritis.

[0045] After expression of a particular light chain variable gene is identified as correlating with a disease, the expression of the light chain variable genes may be used to diagnose the disease, monitor disease progression, aid in prognosis, identify likely or potential sequelae of the disease associated with a particular light chain variable gene, predict the etiology of the disease or the response of the disease to particular forms of therapy. For example, a disease could be diagnosed if the pattern of detected hybridization complexes of the subject tested resembles the pattern of detected hybridization complexes of a diseased subject. As mentioned above, light chain variable gene B2 is associated with formation of amyloid fibrils in 10% of multiple myeloma patients. As an example, the microarray could be used to determine if individuals suffering from multiple myeloma are expressing light chain variable gene B2 using the microarray and tailor treatment options and determine disease prognosis based on the results.

[0046] As one of skill in the art will appreciate, expression of a particular light chain variable gene may be evaluated by any suitable means. For example, expression could be measured directly by measuring hybridization to an oligonucleotide encoding the light chain variable gene, or a complement thereof. Either the oligonucleotide or the target sample may be detectably labeled to visualize hybridization, and hybridization may be performed in any suitable format. Alternatively, expression may be detected by performing real time PCR on the target DNA using a pair of primers that hybridize to sequences within, partially overlapping or flanking the sequence encoding the light chain variable gene. Once a particular light chain variable gene of interest is identified, primer pairs may be designed using available sequence information.

[0047] The present invention also provides methods of evaluating the ability of a therapeutic agent to alter the expression of a light chain variable gene or the repertoire as a whole. First, the light chain variable gene expression of a subject with a disease is assessed using the microarray. Then the subject is treated with the therapeutic agent or undergoes a therapeutic treatment. The light chain variable gene expression is assessed again after treatment and compared to the light chain variable expression prior to treatment to determine whether the therapeutic agent or treatment affected the light chain variable repertoire. A change in light chain variable expression is indicative of effectiveness of the therapeutic agent or treatment.

[0048] The present invention also provides kits for performing the methods described herein. A kit may comprise a microarray comprising oligonucleotide species capable of hybridizing to a sequence encoding at least a portion of a light chain variable region, or a complement thereof. Suitably kits may also comprise antibodies used to sort for B cells, primers for generating the target polynucleotides, reagents needed to label the target polynucleotides and/or other reagents necessary to perform the methods described herein.

[0049] The following examples are meant to be illustrative only and are not intended as a limitation on the concepts and principles of the invention.

EXAMPLES

[0050] Oligonucleotide sequence selection. There are 82 human and 99 mouse functional light chain variable genes. In humans, 6 pairs have identical sequences, i.e., they are duplicate genes, and are not distinguishable. There are reports of pseudogenes in both mouse and human, but these genes were not included because they are considered to be nonfunctional. However, these and other genes may be included if they are found to be misclassified and are indeed functional. Oligonucleotides specific for each of the functional mouse and human light chain variable genes were selected from the genetic sequences that are available on the NCBI website under the heading "Ig Germline Genes".

[0051] Unique sequences ranging from 65-70 base pairs from each V region light chain (both kappa and lambda) were identified by genome scans of germline sequences. The sequence length was chosen to allow for use of high stringency hybridization conditions and thus optimize the specificity. The oligonucleotide set used in the microarray experiments described herein is shown in Table 2 and Table 3. The

oligonucleotides were chosen to have minimal cross-hybridization with other variable light chain genes, to have melting temperatures of 70° C. +/-3° C. and a G-C content of 35% to 55%. The oligonucleotides were also selected to have low potential to self-fold, therefore maximizing their target size for spotting onto the slide. See Wang et al. *Genome Biology* 4:R5 (2003), which is incorporated herein by reference in its entirety. The following computer programs were also used in selection of the oligonucleotides:

- [0052] 1. Oligowiz
- [0053] 2. Array designer
- [0054] 3. NCBI mouse gene database
- [0055] 4. Blast
- [0056] 5. Mfold
- [0057] 6. Repeatmasker
- [0058] 7. Bioperl Project
- [0059] 8. EMBOSS.

[0060] In addition to the light chain variable region oligonucleotides, positive and negative control oligonucleotides were selected based on the same criteria. The kappa and lambda constant region oligonucleotides were used to normalize the samples for the amount of light chain present in each sample. Other control oligonucleotides included Beta actin, CD19, CD20, B220, CD 138, and Blimp-1.

[0061] Preparation of the microarray. Each of the oligonucleotides listed in Table 2 and Table 3 was generated (Integrated DNA Technologies, Coralville, Iowa). These oligonucleotides were suspended in microarray printing buffer (150 mM sodium phosphate) and printed at the University of Illinois, Urbana-Champaign using an Omni-Grid 100 Microarrayer (Gene Machines, San Carlos, Calif.) onto an UltraGAPS Coated Slide (Corning, Acton, Mass.). Both positive control (CD19, CD20, B220, actin and GAPDH) and negative control (CD138, blank and Blimp-1) genes were incorporated into the microarray. Each oligonucleotide was printed in ten replicates onto a glass slide (either randomly or next to each other) and stored in vacuum sealed packaging until ready for use. Before the sample was applied to the microarray, the microarray was prehybridized in 5xSSC, 0.1% SDS and 0.1 mg/mL BSA at 42° C. for 45 minutes.

[0062] Isolation of B cells. B cells were sorted, based on the cell phenotype of CD19+ CD20+CD138- (mouse B cells sorts used CD19+CD138-), using fluorescent activated cell sorting (FACS). Human B cells were sorted by gating on CD19+, CD20+, CD138- cells. Mouse B cells were sorted by gating on CD19+, CD 138- cells. Cells were sorted directly into RNeasy (Ambion, Austin, Tex.) which prevents RNA degradation and allows samples to be stored indefinitely.

[0063] Plasma cells express CD138 and are a source of potential contamination because they express 1,000-10,000 fold more light chain than B cells and a single plasma cell could mask differential light chain variable region expression. Thus, several additional measures were taken to ensure that plasma cells were not present in the samples. First, the FACS selects against incorporation of plasma cells by selecting only CD138- cells. Additionally, only 100 cells are

sorted into one sample (but many samples are collected from one individual) to minimize contamination. Finally, a reverse transcriptase-polymerase chain reaction (RT-PCR) capable of detecting plasma cell specific gene expression with single cell sensitivity was utilized to ensure the samples were plasma cell free. The PCR detects plasma cell-specific Blimp-1 gene expression (forward primer: TCTGT-TCAAGCCGAGGCATCCTTA (SEQ ID NO:366) and reverse primer: TCCAAAGCGTGTCCCTTCGGTAT (SEQ ID NO:367)). 1 µL of cDNA from the aRNA protocol (before any amplification) is used as the template with Platinum Taq DNA Polymerase using the recommended protocol (Invitrogen, Carlsbad, Calif.). If plasma cell contamination was detected in a sample, the sample was discarded.

[0064] Preparation of the target polynucleotides from B cells. RNA was isolated from the sorted B cells using TRIZOL (Invitrogen, Carlsbad, Calif.). Samples containing 100 B cells do not contain sufficient RNA for direct analysis in a microarray. Therefore, an established antisense RNA (aRNA) amplification protocol designed to minimize introduction of bias was used (MEGAscript T7 Kit, Ambion, Austin, Tex.). Two rounds of amplification provided sufficient RNA for hybridization. Amide-modified UTP was incorporated in the second round product and was used for fluorescent labeling of the samples. The RNA samples were labeled using ULYSIS dyes according to the manufacturer's instructions (Invitrogen-Molecular Probes, Eugene, Ore.).

[0065] Hybridization of the target polynucleotides to the microarray and scanning. Labeled aRNA samples were mixed with 1 µg of poly-A RNA as a blocking reagent and hybridization buffer (50% formamide, 5xSSC, 0.1% SDS and 0.1 mg/mL BSA) and added to the microarray slide. Hybridizations were performed in a 45° C. water bath overnight. After hybridization, microarrays were washed in 2xSSC, 0.1% SDS at 42° C. for 5 minutes, two times in 1xSSC at room temperature, two times in 0.1xSSC, and water for 30 seconds. Slides were then dried by centrifugation at 2,500 RPMs and immediately scanned using Axon GenePix 4000B (Molecular Devices, Sunnyvale, Calif.). Data analysis was performed on the scanned image using commercially available software and software designed in our lab. (GeneSpring, Agilent, Palo Alto).

[0066] Specificity of the microarray. To establish that the selected oligonucleotide sequences (represented in Table 2) were specific for the indicated light chain variable regions, RNA prepared from human light chain variable gene clones was used in the array. The B cell clones were obtained through a Material Transfer Agreement with the Mayo Clinic (Rochester, Minn.) and each of the light chain variable regions is known. FIG. 1 is a representative example of microarray data from a single B cell clone known to express the B3 light chain. This experiment allows for assessment of the level of cross-hybridization of the oligonucleotides in the microarray and provides an example of how this method can be used to characterize the light chain in plasma cell diseases. Similar experiments have been performed using the L12 light chain clone and are planned for the O8/18, V1-19, V1-16 and V1-22 light chains. Specificity of the mouse light chain oligonucleotides has been determined using RNA from hybridomas.

[0067] Use of Reference Sequence in Light Chain Microarray. A reference sequence is used to control for

differences in probe hybridization efficiency, spotting inconsistencies and print batch differences and other variations that may influence spot intensity. The reference sequence is composed of equal-molar concentrations of DNA oligonucleotides complementary to the light chain probes. A large amount of the reference sequence has been synthesized and stored. It could also be re-synthesized if necessary. The reference sample is labeled with one fluorophore and the sample nucleic acid is labeled with a second fluorophore. Thus, spots or probe hybridization efficiency will be reflected in the intensity reading of the reference sample (a spot/probe with low hybridization efficiency will have a low intensity, while a spot/probe with high hybridization efficiency will have a high intensity). Thus, the sample of interest can be normalized on a probe-by-probe (gene-by-gene) basis according to the reference sample intensity of a particular probe.

[0068] Cross-hybridization Quantification and Incorporation into Data Analysis. The relatedness of the light chain V genes is reflected in the germline sequence similarity. In some cases, V genes have been duplicated and have not diverged (for example, O2 and O12 are identical, as are others). Other V genes have diverged slightly and share significant sequence similarity. While the oligonucleotide species described above were designed to exploit all possible differences, some of them are very similar to V genes other than the gene they were designed to interrogate. Thus, cross-hybridization between an oligonucleotide species and a related V gene is a concern. One example of this cross-hybridization is demonstrated in FIG. 1 where the B3 nucleic acid hybridizes to other oligonucleotide species, including the oligonucleotide species designed to hybridize to L5. We are currently in the process of testing each V gene sequence individually to determine the extent of cross-hybridization with all of the oligonucleotides species (we have completed over 60% of these hybridizations). When cloned V gene sequences were not available, the complementary sequence to that probe was synthesized, labeled and hybridized to the array. The data from these hybridizations is being compiled in a matrix. This matrix of cross-hybridization will then contain all of the information necessary to distinguish a real signal from cross-hybridization. This will be done by crossing the data generated by a sample with the inverse of this matrix. The output of this computation is the true signal.

[0069] Repertoire differences in autoimmune-prone and non-autoimmune prone mice. C57/B6 mice with the 56R heavy-chain transgene develop auto-antibodies at a very young age, while Balb/c mice (without any transgene) remain healthy and do not develop auto-antibodies. See Sekiguchi et al., *J. Immunol.* 176:6879-6887 (2006). The repertoire from two 56R transgenic C57/B6 mice with detectable auto-antibodies was compared with six Balb/c mice without any evidence of autoimmunity using the light chain variable region microarray and the results are depicted in FIG. 2.

[0070] Briefly, B cells were sorted for each mouse independently, RNA was prepared and hybridization with the microarray performed as described in detail above. After hybridization, image analysis was completed using Axon GenePix and the median intensity for all replicate spots averaged. Intensity levels across samples were normalized by comparison with kappa-constant values from the same

sample. These normalized values were then averaged for the 56R transgenic C57/B6 mice and the Balb/c mice. The Balb/c normalized and averaged values were then subtracted from the 56R transgenic C57/B6 normalized and averaged values for each gene. Thus, a positive value in FIG. 2 corresponds to a light chain being overrepresented in a 56R transgenic C57/B6 autoimmune mouse, while a negative value corresponds to overrepresentation of a light chain variable region in Balb/c mice. The following L-chain V gene spots had values below background and were not included in the analysis: 12-46, 21-3, 8-16, 8-34, ae4 and ba9.

[0071] As shown in FIG. 2, several of the light chain variable genes were overrepresented in the autoimmune prone transgenic mice, namely 23-48, Bt20, gj38c, V11, and V12. Several of these light chain variable genes, including Bt20 and gj38c have been linked to autoimmune disease in this mouse model using traditional B cell cloning and sequencing or PCR-based analysis of the light chain variable gene. See Li et al., *Immunity* 15:947:957 (2001) and Table 1.

[0072] L-chain repertoire changes with induced autoimmunity. Chronic graft-versus-host (cGvH) disease was induced by injection of allogeneic CD4+ T cells from a bm12 mouse into a 56R heavy-chain transgenic B6 mouse as previously described. See Sekiguchi et al., *Proc. Natl. Acad. Sci. U.S.A.* 84:9150-9154 (2003) which is incorporated herein by reference in its entirety. The B cell light chain repertoire was sampled 20 days post-induction using the light chain variable gene microarray as described above and the results are presented in FIG. 3. Anti-DNA antibodies were increased at day 20 post-induction in this mouse compared with day 0 and were higher than a littermate control 56R transgenic mouse that did not undergo cGvH induction as measured by ELISA.

[0073] Briefly, RNA was prepared from 100 B cells from a cGvH-induced 56R transgenic mouse and a control 56R transgenic mouse. The RNA was labeled and hybridized to the array. The microarray image was analyzed using the Axon GenePix, and the median intensity for all replicate spots was averaged for each sample. Intensity levels were normalized by comparing the average intensity of each light chain variable gene with the kappa-constant gene intensity for the same sample. These values from the control (no cGvH) 56R mouse were then subtracted from the day 20 cGvH 56R values for each gene and plotted on the y-axis. Positive values correspond to an expansion of light chain variable genes after induced autoimmunity, and negative values correspond to light chain variable genes that are underrepresented after induction of autoimmunity.

[0074] As shown in FIG. 3, several of the light chain variable genes were overrepresented in the autoimmune mice at day 20 post-induction, while other light chain variable genes were underrepresented in these animals as compared to untreated control transgenic mice. The light chain variable genes overrepresented and underrepresented in this model were distinct from those identified as overrepresented in 56R as compared to Balb/c mice in FIG. 2 and are distinct from the previously reported light chain variable genes linked to autoimmunity Sekiguchi et al., *J. Immunol.* 176:6879-6887 (2006), Table 1, and unpublished data.

[0075] Light Chain Variable Detection in Human Autoimmune Disease. Reports in the literature suggest multiple

sclerosis (MS) patients display a restricted cerebral-spinal fluid (CSF) B cell repertoire. See Monson et al., *J. Neuroimmunol.* 158:170-181 (2005) and Colombo et al., *J. Immunol.* 164:2782-2789 (2000) which are incorporated herein by reference in their entireties. Therefore, this disease was chosen to test the microarray and determine if the light chain variable regions identified in Table 1 were found in MS patients. B cells were harvested from the CSF of an untreated MS patient and from three individuals who do not have MS. The cells were sorted, the RNA isolated, amplified, labeled and hybridized to the microarray as described above. FIG. 4 depicts the light chain variable gene expression from the MS patient normalized to the kappa constant gene after averaging the replicates. The data demonstrate that a subset of light chain variable genes is expressed in the MS patient. Notably, several of the expressed genes correlate to the light chains hypothesized to be important in autoimmune pathology listed in Table 1, namely B2, O8/O18, L25 and V2-15. FIG. 5 shows the light chain variable gene expression as fluorescence intensity normalized to the kappa constant region as a ratio to the light chain variable gene expression in three healthy individuals. The light chain variable regions that were differentially expressed are noted in the Figure. As depicted in FIG. 5, the B2 light chain was overrepresented in the MS patient as compared to the healthy individuals and this chain has

structural properties similar to pathogenic light chains in the mouse as indicated in Table 1.

[0076] Light Chain Repertoire Differences in SLE. This method has detected V gene light chain repertoire differences between an individual with a clinical diagnosis of SLE and a healthy individual with no known autoimmunity. In this example, peripheral blood was isolated from these two individuals. B cells of the CD20⁺CD138⁻CD27⁻CD38⁻ phenotype were sorted and prepared as described above. Each sample was labeled with Alexa 647 dyes and mixed with a reference sequence labeled with Alexa 555 (Invitrogen-Molecular Probes, Eugene Oreg.). The samples were independently hybridized, washed and scanned. Comparisons were made by performing global intensity normalization for each fluorescent channel on each array. These were used to generate a ratio of sample:reference, and this sample:reference ratio was compared between arrays to generate FIG. 6. As can be seen from this figure, some V genes are overrepresented in this SLE patient compared with this healthy individual (the points above the line such as V4-4, V4-6, L24 and A27). Additionally, some V genes are underrepresented in this SLE patient such as V5-4 and V5-1.

[0077] Various features of the invention are set forth in the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 367

<210> SEQ ID NO 1

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 1

Ser Thr Thr Val Thr Gln Ser Pro Ala Ser Leu Ser Met Ala Ile Gly
1 5 10 15

Glu Lys Val Thr Ile Arg Cys Ile Thr Ser Thr Asp Ile Asp Asp Asp
20 25 30

Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile
35 40 45

Ser Glu Gly Asn Thr Leu Arg Pro Gly Val Pro Ser Arg Phe Ser Ser
50 55 60

Ser Gly Tyr Gly Thr Asp Phe Val Phe Thr Ile Glu Asn Met Leu Ser
65 70 75 80

Glu Asp Val Ala Asp Tyr Tyr Cys Leu Gln Ser Asp Asn Leu Pro
85 90 95

<210> SEQ ID NO 2

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 2

Glu Thr Thr Val Thr Gln Ser Pro Ala Ser Leu Ser Val Ala Thr Gly
1 5 10 15

Glu Lys Val Thr Ile Arg Cys Ile Thr Ser Thr Asp Ile Asp Asp Asp

-continued

	20		25		30										
Met	Asn	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Glu	Pro	Pro	Lys	Leu	Leu	Ile
	35						40					45			
Ser	Glu	Gly	Asn	Thr	Leu	Arg	Pro	Gly	Val	Pro	Ser	Arg	Phe	Ser	Ser
	50					55					60				
Ser	Gly	Tyr	Gly	Thr	Asp	Phe	Val	Phe	Thr	Ile	Glu	Asn	Thr	Leu	Ser
	65				70					75				80	
Glu	Asp	Val	Ala	Asp	Tyr	Tyr	Cys	Leu	Gln	Ser	Asp	Asn	Met	Pro	
				85					90					95	

<210> SEQ ID NO 3
 <211> LENGTH: 95
 <212> TYPE: PRT
 <213> ORGANISM: Mus musculus

<400> SEQUENCE: 3

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Leu	Gly
1				5					10					15	
Gly	Lys	Val	Thr	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asp	Ile	Asn	Lys	Tyr
			20					25					30		
Ile	Ala	Trp	Tyr	Gln	His	Lys	Pro	Gly	Lys	Gly	Pro	Arg	Leu	Leu	Ile
			35				40					45			
His	Tyr	Thr	Ser	Thr	Leu	Gln	Pro	Gly	Ile	Pro	Ser	Arg	Phe	Ser	Gly
	50					55					60				
Ser	Gly	Ser	Gly	Arg	Asp	Tyr	Ser	Phe	Ser	Ile	Ser	Asn	Leu	Glu	Pro
	65				70					75				80	
Glu	Asp	Ile	Ala	Thr	Tyr	Tyr	Cys	Leu	Gln	Tyr	Asp	Asn	Leu	Leu	
				85					90					95	

<210> SEQ ID NO 4
 <211> LENGTH: 103
 <212> TYPE: PRT
 <213> ORGANISM: Mus musculus

<400> SEQUENCE: 4

Gln	Leu	Val	Leu	Thr	Gln	Ser	Ser	Ser	Ala	Ser	Phe	Ser	Leu	Gly	Ala
1				5					10					15	
Ser	Ala	Lys	Leu	Thr	Cys	Thr	Leu	Ser	Ser	Gln	His	Ser	Thr	Tyr	Thr
			20					25					30		
Ile	Glu	Trp	Tyr	Gln	Gln	Gln	Pro	Leu	Lys	Pro	Pro	Lys	Tyr	Val	Met
			35				40					45			
Glu	Leu	Lys	Lys	Asp	Gly	Ser	His	Ser	Thr	Gly	Asp	Gly	Ile	Pro	Asp
	50					55					60				
Arg	Phe	Ser	Gly	Ser	Ser	Ser	Gly	Ala	Asp	Arg	Tyr	Leu	Ser	Ile	Ser
	65				70					75				80	
Asn	Ile	Gln	Pro	Glu	Asp	Glu	Ala	Ile	Tyr	Ile	Cys	Gly	Val	Gly	Asp
				85					90					95	
Thr	Ile	Lys	Glu	Gln	Phe	Val									
			100												

<210> SEQ ID NO 5
 <211> LENGTH: 99
 <212> TYPE: PRT
 <213> ORGANISM: Mus musculus

<400> SEQUENCE: 5

-continued

```

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1           5           10          15
Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20          25          30
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35          40          45
Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
50          55          60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65          70          75          80
Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85          90          95

Glu Asp Pro

```

```

<210> SEQ ID NO 6
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

```

```

<400> SEQUENCE: 6

```

```

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ala Ala Ser Val Gly
1           5           10          15
Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Tyr Ser
20          25          30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile
35          40          45
Tyr Asn Ala Asn Ser Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly
50          55          60
Ser Gly Ser Gly Thr Gln Tyr Ser Met Lys Ile Asn Ser Met Gln Pro
65          70          75          80
Glu Asp Thr Ala Thr Tyr Phe Cys Lys Gln Ala Tyr Asp Val Pro
85          90          95

```

```

<210> SEQ ID NO 7
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

```

```

<400> SEQUENCE: 7

```

```

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
1           5           10          15
Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn
20          25          30
Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val
35          40          45
Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50          55          60
Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser
65          70          75          80
Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro
85          90          95

```

```

<210> SEQ ID NO 8
<211> LENGTH: 95

```

-continued

```

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
           20           25           30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
           35           40           45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
           50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro
           85           90           95

```

```

<210> SEQ ID NO 9
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1           5           10           15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
           20           25           30
Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
           35           40           45
Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser
           50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
65           70           75           80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asp Tyr Asn Leu Pro
           85           90           95

```

```

<210> SEQ ID NO 10
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

Glu Thr Thr Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Thr Pro Gly
1           5           10           15
Asp Lys Val Asn Ile Ser Cys Lys Ala Ser Gln Asp Ile Asp Asp Asp
           20           25           30
Met Asn Trp Tyr Gln Gln Lys Pro Gly Glu Ala Ala Ile Phe Ile Ile
           35           40           45
Gln Glu Ala Thr Thr Leu Val Pro Gly Ile Pro Pro Arg Phe Ser Gly
           50           55           60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Ile Glu Ser
65           70           75           80
Glu Asp Ala Ala Tyr Tyr Phe Cys Leu Gln His Asp Asn Phe Pro
           85           90           95

```

-continued

```

<210> SEQ ID NO 11
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11
Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro
85           90           95

```

```

<210> SEQ ID NO 12
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12
Glu Ile Val Met Thr Gln Ser Pro Pro Thr Leu Ser Leu Ser Pro Gly
1           5           10           15
Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20           25           30
Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35           40           45
Ile Tyr Gly Ala Ser Thr Arg Ala Thr Ser Ile Pro Ala Arg Phe Ser
50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
65           70           75           80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asp His Asn Leu Pro
85           90           95

Pro

```

```

<210> SEQ ID NO 13
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13
Ser Tyr Glu Leu Thr Gln Pro Ser Ser Val Ser Val Ser Pro Gly Gln
1           5           10           15
Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala
20           25           30
Arg Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35           40           45
Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50           55           60
Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu
65           70           75           80

```

-continued

Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Leu
85 90 95

<210> SEQ ID NO 14
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Ser Tyr Glu Leu Thr Gln Leu Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Gly Glu Asn Tyr Ala
20 25 30
Asp Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Glu Leu Val Ile Tyr
35 40 45
Glu Asp Ser Glu Arg Tyr Pro Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Thr Ser Gly Asn Thr Thr Thr Leu Thr Ile Ser Arg Val Leu Thr Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Leu Ser Gly Asp Glu Asp Asn Pro
85 90 95

<210> SEQ ID NO 15
<211> LENGTH: 99
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

Gln Pro Val Leu Thr Gln Ser Ser Ser Ala Ser Ala Ser Leu Gly Ser
1 5 10 15
Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gly His Ser Ser Tyr Ile
20 25 30
Ile Ala Trp His Gln Gln Gln Pro Gly Lys Ala Pro Arg Tyr Leu Met
35 40 45
Lys Leu Glu Gly Ser Gly Ser Tyr Asn Lys Gly Ser Gly Val Pro Asp
50 55 60
Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr Leu Thr Ile Ser
65 70 75 80
Asn Leu Gln Phe Glu Asp Glu Ala Asp Tyr Tyr Cys Glu Thr Trp Asp
85 90 95

Ser Asn Thr

<210> SEQ ID NO 16
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

ctgcaggtct agtcaagcc tcgtatacag tgatggaac acctacttga attggtttca 60
gcagagg 67

<210> SEQ ID NO 17
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

-continued

ctcaccatca atagcctgga agctgaagat gctgcaacgt attactgtca tcagagtagt 60

agtttac 67

<210> SEQ ID NO 18
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

gacttcactc tcaccatcag cagactggag cctgaagatt ttgcagtgta ttactgtcag 60

cagtatg 67

<210> SEQ ID NO 19
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19

gatctgggac agatttcacc ttaccatca gtagcctgga agctgaagat gctgcaacat 60

attactg 67

<210> SEQ ID NO 20
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20

catctcctgc aagtctagtc agagcctcct gcatagtgat ggaaagacct atttgattg 60

gtacctg 67

<210> SEQ ID NO 21
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

gatcaggcac agattttaca ctgaaaatca gcagagtgga ggctgaggat gttggggttt 60

attactg 67

<210> SEQ ID NO 22
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22

tctgcatctg taggagacag agtcaccatc acttgccggg cgagtcaggg cattagcaat 60

tatttag 67

<210> SEQ ID NO 23
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

ctacttgagt tggcttcagc agaggccagg ccagcctcca agactcctaa tttataagat 60

ttctaac 67

-continued

<210> SEQ ID NO 24
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

ctctcacaat cagcagcctg cagcctgaag attttgaac ttattactgt ctacagcata 60
atagtta 67

<210> SEQ ID NO 25
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

catctccttc aggtctagtc aaagcctcgt acacagtgat gaaacacct acttgagttg 60
gcttcag 67

<210> SEQ ID NO 26
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26

gagaagctgc tattttcatt attcaagaag ctactactct cgttcctgga atcccacctc 60
gattcag 67

<210> SEQ ID NO 27
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 27

catcaactgc aagtcacgcc agagtgtttt atacagctcc aacaataaga actacttagc 60
ttggtac 67

<210> SEQ ID NO 28
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 28

gtaggagaca gagtcacat cacttgctcg gogagtcagg gcattagcaa ttatttagcc 60
tggtttc 67

<210> SEQ ID NO 29
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

ctcacatca gcagcctgca gcctgaagat tttgcagttt attactgtca gcaggatcat 60
aacttac 67

<210> SEQ ID NO 30
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 30
ctctcacat cagcagcctg cagcctgaag atttgcaac ttattactgt ctacaagatt 60
acaatta 67

<210> SEQ ID NO 31
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 31
tggtatcagc agaaaccagg gaaagccct aagctcctga tctatgatgc ctccagtttg 60
gaaagtg 67

<210> SEQ ID NO 32
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 32
ctctcacat cagcagcctg cagcctgaag atttgcaac ttattactgc caacagtata 60
atagtta 67

<210> SEQ ID NO 33
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 33
ctctcacat cagcagcctg cagtctgaag atttgcagt ttattactgt cagcagtata 60
ataactg 67

<210> SEQ ID NO 34
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 34
tggtatcagc agaaaccagg gaaagctcct aagctcctga tctatgatgc ctccagtttg 60
gaaagtg 67

<210> SEQ ID NO 35
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 35
catcttctgt gtctgcatct gtaggagaca gagtcacat cacttgctgg gcgagtcagg 60
gtattag 67

<210> SEQ ID NO 36
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 36

-continued

ttcactctca ccatcagcag cctagagcct gaagatttg cagtttatta ctgtcagcag 60

cgtagca 67

<210> SEQ ID NO 37
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 37

gtaggagaca gagtcagtat catttgctgg gcaagtgagg gcattagcag taatttagcc 60

tggatc 67

<210> SEQ ID NO 38
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 38

ctctcacat cagcagcctg cagcctgaag atttgcaac ttattactgt caacagtatt 60

atagtac 67

<210> SEQ ID NO 39
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 39

catctacagg agacagagtc accatcagtt gtcggatgag tcagggcatt agcagttatt 60

tagcctg 67

<210> SEQ ID NO 40
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 40

ctcacatca gcagcctgca gcttgaagat tttgcagttt attactgtca gcaggattat 60

aacttac 67

<210> SEQ ID NO 41
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 41

gacagatttc actctcacca tcagcagcct gcagcctgaa gattttgcaa cttactattg 60

tcaacag 67

<210> SEQ ID NO 42
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 42

ctctcacaat cagcagcctg cagcctgaag atttgcaac ttattactgt caacagetta 60

atagtta 67

-continued

<210> SEQ ID NO 43
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 43

catctacagg agacagagtc accatcactt gtcgggagag tcagggtatt agcagttatt 60
tagcctg 67

<210> SEQ ID NO 44
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 44

gtctagttag agcctcttgg atagtgatga tggaaacacc tatttgact ggtacctgca 60
gaagcca 67

<210> SEQ ID NO 45
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 45

gagcattagc agctatttaa attggtatca gcagaaacca gggaaagccc ctaagctcct 60
gatctat 67

<210> SEQ ID NO 46
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 46

cagttattta aattggtatc gccagaaacc agggaaagtt cctaagctcc tgatctatag 60
tgcatcc 67

<210> SEQ ID NO 47
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47

gtaggagaca gagtcacat cacttgccag gogagtcagg acattagcaa ctatttaaat 60
tggatc 67

<210> SEQ ID NO 48
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 48

gcagagggtc accatctcct gttctggaag cagctccaac atcggaaata atgctgtaaa 60
ctggtag 67

<210> SEQ ID NO 49
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 49
gcagagggtc accatctctt gttctggaag cagctccaac atcggaagta atactgtaaa 60
ctggtag 67

<210> SEQ ID NO 50
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 50
gcagagggtc accatctctt gttctggaag cagctccaac atcggaagta attatgtata 60
ctggtag 67

<210> SEQ ID NO 51
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 51
ctccctggcc atcaactggac tccagtctga ggatgaggct gattattact gcaaagcatg 60
ggataac 67

<210> SEQ ID NO 52
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 52
caaactcctc atttatgaca ataataagcg accctcaggg attcctgacc gattctctgg 60
ctccaag 67

<210> SEQ ID NO 53
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 53
gtcagtcacc atctcctgca ctggaaccag cagtgacggt ggtggttata actatgtctc 60
ctggtag 67

<210> SEQ ID NO 54
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 54
ccaccctccc aaactcctat cctacagga taacaaccgg ccctcagga tctcagagag 60
attctct 67

<210> SEQ ID NO 55
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 55

-continued

ctgtgatcta tgaggataac caaagaccct ctgggggtccc tgatcggttc tctggctcca 60
tcgacag 67

<210> SEQ ID NO 56
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 56

gtcagtcacc atctcctgca ctggaaccag cagtgatggt ggtggttata actatgtctc 60
ctggtac 67

<210> SEQ ID NO 57
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 57

caaaactcatg atttatgagg tcagtaatcg gccctcaggg gtttctaate gcttctctgg 60
ctccaag 67

<210> SEQ ID NO 58
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 58

ctctgggctc caggctgagg acgaggctga ttattactgc agcttatata caagcagcag 60
cactttc 67

<210> SEQ ID NO 59
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 59

ctgacaatct ctgggtccca ggctgaggac gaggtgatt attactgctg ctcatatgca 60
ggtagtag 68

<210> SEQ ID NO 60
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 60

ctctgggctc aagtccgagg ttgaggctaa ttatcactgc agcttatatt caagtagtta 60
cactttc 67

<210> SEQ ID NO 61
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 61

gataaatatg ctgtctggta tcagcagaag ccaggccagt cccctgtgct ggtcatctat 60
caagatag 68

-continued

<210> SEQ ID NO 62
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 62
tagtcacatt gaccatcagt ggagtccagg cagaagacga ggctgactat tactgtctat 60
cagcaga 67

<210> SEQ ID NO 63
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 63
cttgggacag acagtcagga tcacatgccca aggagacagc ctcagaagct attatgcaag 60
ctggtac 67

<210> SEQ ID NO 64
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 64
ctgagttggt gatatacga gatagtgagc ggtaccctgg aatccctgaa cgattctctg 60
ggtccac 67

<210> SEQ ID NO 65
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 65
gacaacagtc acgttgacca tcagtggagt ccaggcagaa gatgaggctg actattactg 60
tcaatcag 68

<210> SEQ ID NO 66
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 66
ctgggacaga cggccaggat tacctgtggg ggaaacaaca ttggaagtaa aaatgtgcac 60
tggtacc 67

<210> SEQ ID NO 67
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 67
gttactatcc aaactggttc cagcagaaac ctggacaagc acccagggca ctgatttata 60
gtacaag 67

<210> SEQ ID NO 68
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 68
gacactgatt tatgatataca gcaacaaaca ctcctggaca cctgcccggg tctcaggctc 60
cctcctt 67

<210> SEQ ID NO 69
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 69
ctggaggagc agtcacactc acttggtggc tgagctctgg ctcagtctct actagttact 60
accccag 67

<210> SEQ ID NO 70
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 70
aatacagga ttttactcat ctccgggctc cagtctgagg atgaggctga ctattactgt 60
atgattt 67

<210> SEQ ID NO 71
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 71
aatgcagga ttttactcat ctctgggctc cagtctgagg atgaggctga ctattactgt 60
atgattt 67

<210> SEQ ID NO 72
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 72
aatgcagga ttttagtcat ctctgggctc cagtctgagg atgaggctga ctattactgt 60
atgattt 67

<210> SEQ ID NO 73
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 73
ggtaccaaca aaagccaggg aaccctcccc ggtatctcct gtactaccac tcagactcca 60
ataaggg 67

<210> SEQ ID NO 74
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 74

-continued

gtaccagcag aagccaggga gctctcccag gttattcctg taccactact cagactcaga 60
caagcag 67

<210> SEQ ID NO 75
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 75

catcgaatgg tatcaacaga gaccagggag gtccccccag tatataatga aggttaagag 60
tgatggc 67

<210> SEQ ID NO 76
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 76

gaatcggtac ctgaccatca agaacatcca ggaagaagat gagagtgact accactgtgg 60
ggcagac 67

<210> SEQ ID NO 77
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 77

ctacctcacc atctccaacc tccagtttga ggatgaggct gattattact gtgagacctg 60
ggacagt 67

<210> SEQ ID NO 78
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 78

tcattctatgg taacagcaat cggccctcag gggccctga ccgattctct ggctccaagt 60
ctggcacctc a 71

<210> SEQ ID NO 79
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 79

cctgtgctgg tcgtctatga tgatagcgc cggccctcag ggatccctga gcgattctct 60
ggctccaact 70

<210> SEQ ID NO 80
<211> LENGTH: 72
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 80

tcaccttgac catcagcggg gccaggttg aggatgaggc tgactattac tgttactctg 60
cggctgacaa ca 72

-continued

<210> SEQ ID NO 81
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 81
cagcaaacga ccctccggga tccttgagag attctctggc tccagctcag ggacaatggc 60
caccttgact atc 73

<210> SEQ ID NO 82
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 82
tgtgtgtgtc atctatagcg atagcaaccg gccctcaggg atcccctgagc gattctctgg 60
ctccaaccca g 71

<210> SEQ ID NO 83
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 83
gagaagggcc ctcggtactt gatgaagctt aacagtgatg gcagccacag caagggggac 60
gggatccctg atc 73

<210> SEQ ID NO 84
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 84
ttttaatagt cattccaat atgagatgcg ttgttacagg aagtccttg ccatcctaaa 60
agccacc 67

<210> SEQ ID NO 85
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 85
gctgtgactt tggttatct gatcttctgc ctgtgttccc ttgtggcat tcttcatctt 60
caaagag 67

<210> SEQ ID NO 86
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 86
caatacagaa cccattccat ttatctttct acagggctga cattgtggca cattcttaga 60
gttacca 67

<210> SEQ ID NO 87
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 87
gaataacttc tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc 60
gggtaac 67

<210> SEQ ID NO 88
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 88
ctgggacaca gtattctatg aagatcaaca gcatgcagcc tgaagatacc gcaacttatt 60
tctgtaaaca 70

<210> SEQ ID NO 89
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 89
gcaaaaacct tagcagatgg tgtgccatca aggttcagtg gcagtggatc aggaacacaa 60
tattctctca 70

<210> SEQ ID NO 90
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 90
agttttctct gaagatcaac agcctgcagc ctgaagattt tgggagtat tactgtcaac 60
atcattatgg 70

<210> SEQ ID NO 91
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 91
gcaacaaact tagcagatgg tgtgccatca aggttcagtg gcagtggatc aggcaacacag 60
tattccctca 70

<210> SEQ ID NO 92
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 92
tttcaactctc accatcagca atatgcagtc tgaagacctg gcagattatt tctgccagca 60
atatagcagc 70

<210> SEQ ID NO 93
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 93

-continued

ctctcacccat tagcaatgtg caatctgaag acctggcaga ttatttctgt ctgcaacatt 60
ggaattatcc 70

<210> SEQ ID NO 94
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 94

ggtactaatg tagcctggta tcaacagaaa ccagggcaat ctctaaagc actgatttac 60
tcggcatcct 70

<210> SEQ ID NO 95
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 95

ggacggattt cactttcacc atcagcagtg tgcaggctga agacctggca gtttattact 60
gtcagcaaca 70

<210> SEQ ID NO 96
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 96

cactggggtc cccgatcgct tcacaggcag tggatctgca acagatttca ctctgacct 60
cagcagtgtg 70

<210> SEQ ID NO 97
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 97

ctctcacccat tagcaatgtg cagctctgaag acttggcaga ttatttctgt cagcaatata 60
gcagctatcc 70

<210> SEQ ID NO 98
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 98

tatactctca ccatcagcag tgtgcaggct gaagacctgg cactttatta ctgtcagcaa 60
cattatagca 70

<210> SEQ ID NO 99
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 99

accctggggc cctgatcgc ttcacaggca gtggatctgc aacagatttc actctgacca 60
tcagcagtct 70

-continued

<210> SEQ ID NO 100
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 100
attcctgctt gtatcagcag gagacagggt taccataacc tgcaaggcca gtcagagtgt 60
gagtaatgat 70

<210> SEQ ID NO 101
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 101
caccatctcc tgcagagcca gtgaaagtgt tgaatattat ggcacaagtt taatgcagtg 60
gtaccaacag 70

<210> SEQ ID NO 102
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 102
tcaccctcac cattgatcct gtggaggctg atgatgctgc aacctattac tgcagcaaa 60
ataatgagga 70

<210> SEQ ID NO 103
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 103
ctggctatag ttatatgcac tggtagcaac agaaaccagg acagccaacc aaactcctca 60
tctatcttgc 70

<210> SEQ ID NO 104
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 104
gccaccatct cctgcagagc cagcgaagt gttgataatt atggcattag ttttatgaac 60
tggttccaac 70

<210> SEQ ID NO 105
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 105
gagcactat cttctgcaga gccagccaga gtgtcgatta taatggaatt agttatatgc 60
actggttcca 70

<210> SEQ ID NO 106
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 106
gccaccatct cctgcaagc cagccaaagt gttgattatg atggtgatag ttatatgaac 60
tggtagcaac 70

<210> SEQ ID NO 107
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 107
ctcaccatta atcctgtgga ggctgatgat gttgcaacct attactgtca gcaaagtaat 60
gaggatcctc 70

<210> SEQ ID NO 108
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 108
ctagctatag ttatatgcac tggtagcaac agaaccagg acagccacc aaactcctca 60
tcaagtatgc 70

<210> SEQ ID NO 109
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 109
gacagagggc caccatatcc tgccaagcca gcgaaagtgt cagttttgct ggtacaagtt 60
taatgcactg 70

<210> SEQ ID NO 110
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 110
agtaagaagc tcaccattag ttgcacggcc agtgagagcc tttattcaag caaacacaag 60
gtgcactact 70

<210> SEQ ID NO 111
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 111
gattacactc tcagtatcaa cagtgtgaag cccgaagatg aaggaatata ttactgtctt 60
caaggttaca 70

<210> SEQ ID NO 112
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 112

-continued

ctctcagtat caacagtgtg gaacctgaag atgttgaggt gtattactgt caaaatggtc 60
acagctttcc 70

<210> SEQ ID NO 113
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 113

caggagatag cgtcagtctt tctgcaggg ccagccaaag tattagcaac aacctacact 60
ggtatcaaca 70

<210> SEQ ID NO 114
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 114

ggagatagag tcagtccttc ctgcagggcc agtcaaagta ttagcaacta cctacactgg 60
tatcaacaaa 70

<210> SEQ ID NO 115
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 115

ttctcctgca gggccagtca gagcattggc acaagcatac actggtatca gcaaagaaca 60
aatggttctc 70

<210> SEQ ID NO 116
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 116

gtactggtac cagcagaagt cagatgcctc ccccaaacta tggatttatt acacatccaa 60
cctggctcct 70

<210> SEQ ID NO 117
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 117

ggggctggga tctcttactc tctcacaatc agcagcatgg aggctgaaaa tgatgcaact 60
tattactgcc 70

<210> SEQ ID NO 118
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 118

tgtctgcac tccaggggaa aaggtcacca tgacctgcag ggccagctca agtqtaagtt 60
ccagttactt 70

-continued

<210> SEQ ID NO 119
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 119

atcagaatct tttatggagt ggaaacaaa ggtactgttt ggtctggcac cagtggaaac 60
cagggcaaac 70

<210> SEQ ID NO 120
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 120

ctctcaccat cagcagtggt caggctgaag acctggcagt ttattactgt cagaatgatt 60
atagttatcc 70

<210> SEQ ID NO 121
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 121

ggtcactatg agctgcaaat ccagtcagag tctgctcaac agtagaaccc gaaagaacta 60
cttggttgg 70

<210> SEQ ID NO 122
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 122

tcctccctgg ctatgtcagt aggacagaag gtcactatga gctgcaagtc cagtcagagc 60
cttttaata 70

<210> SEQ ID NO 123
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 123

gaaaaggcca ctatgagctg taagtccagt caaagtgttt tatacagttc aaatcagaag 60
aactacttgg 70

<210> SEQ ID NO 124
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 124

ccgatttcac tcttaccatc agcagtggtc aggtgaaga cctggcagtt tattactgtc 60
agaatgatca 70

<210> SEQ ID NO 125
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 125
ccctagctgt gtcagttgga gagaaggta ctatgagctg caagtccagt cagagccttt 60
tatatagtag 70

<210> SEQ ID NO 126
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 126
tagctagtgg caacaaaat aactacttgg cctggcacca gcagaaacca ggacgatctc 60
ctaaaatgct 70

<210> SEQ ID NO 127
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 127
gagaaacctg ggaaaactaa taagcttctt atctactctg gatccacttt gcaatctgga 60
attccatcaa 70

<210> SEQ ID NO 128
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 128
aactatgcca actgggtcca agaaaaacca gatcatttat tcaactggctc aataggtggt 60
accaacaacc 70

<210> SEQ ID NO 129
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 129
taactatgcc aactgggttc aagaaaaacc agatcattta tcaactggtc taataggtgg 60
taccagcaac 70

<210> SEQ ID NO 130
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 130
acagccactc aagcctocta agtatgtgat ggagcttaag aaagatggaa gccacagcac 60
aggtgatggg 70

<210> SEQ ID NO 131
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 131

-continued

ctcaagtgta agttacatgt actggtacca gcagaagcca ggatcctccc ccaaaccctg 60
gatttatcgc 70

<210> SEQ ID NO 132
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 132

tcacgatcag cagcatggag gctgaagatg ttgccactta ttactgtttt caggggagtg 60
ggtaccacct 70

<210> SEQ ID NO 133
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 133

tattctctca caatcagcag catggaggct gaagatgctg ccacttttta ctgccagcag 60
tacagtggtt 70

<210> SEQ ID NO 134
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 134

actctctcac aatcagcagc atggaggctg aagatgctgc ctcttatttc tgccatcagt 60
ggagttagtta 70

<210> SEQ ID NO 135
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 135

caatcatgtc tgcattctta ggggaggaga tcaccctaac ctgcagtgcc agctcgagtg 60
taagttacat 70

<210> SEQ ID NO 136
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 136

cacttctacc aaattctgga tttataggac atccaacctg gcttcagaag tcccagctcc 60
cttcagtggc 70

<210> SEQ ID NO 137
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 137

tacttgtaact ggtaccagca gaagtcagga tcttcccaa aactctggat ttatagcata 60
tccaacctgg 70

-continued

<210> SEQ ID NO 138
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 138

ctctcacaat cagcagcatg gaggctgaag atgctgccac ttattactgc caccagtatc 60
atcgttcccc 70

<210> SEQ ID NO 139
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 139

tacatgtaat ggttccagca gaagccagga tctccccca aactctggat ttatagcata 60
tccaacctgg 70

<210> SEQ ID NO 140
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 140

catgcactgg taccagcaga agccaggatc ctccccaga ctctggattt atttaacatt 60
caacttggtc 70

<210> SEQ ID NO 141
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 141

ttgttctctc ccagtctcca gcaatcctgt ctgcatctcc aggggagaag gtcacaatga 60
cttgcaaggc 70

<210> SEQ ID NO 142
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 142

gacatctttc tctttcacia tcaacagcat ggaggctgaa gatggtgcca cttattactg 60
tcagcaaagg 70

<210> SEQ ID NO 143
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 143

gccagctcaa gtgtaagtta catgcactgg ttccagcaga agccaggcac ttctcccaaa 60
ctctggattt 70

<210> SEQ ID NO 144
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 144
gtaagttaca tgtactggta ccagcagaag ccaagatcct cccccaacc ctggatttat 60
ctcacatcca 70

<210> SEQ ID NO 145
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 145
tgtaagttac atgtacaggt accagcagaa gccaggatcc tcacccaaac cctggattta 60
tggcacatcc 70

<210> SEQ ID NO 146
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 146
gtaagttaca tgtactggta ccagcagaag ccaggatcct cccccagact cctgatttat 60
gacacatcca 70

<210> SEQ ID NO 147
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 147
ggtctgagag ctcttacct ctgacaatca gctgcatgca ggacgaagtt gctgccactt 60
actattgtca 70

<210> SEQ ID NO 148
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 148
ccatgtatgc atctctagga gagagagtc ctatcacttg caaggcgagt caggacatta 60
atagctatatt 70

<210> SEQ ID NO 149
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 149
cacctattta cattgggtacc tgcagaagcc aggccagtct ccaaagctcc tgatctacaa 60
agtttccaac 70

<210> SEQ ID NO 150
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 150

-continued

aatggaaca cctatttata ttgtacctg cagaagccag gccagtctcc aaagctcctg 60
atctacaggg 70

<210> SEQ ID NO 151
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 151

gtcagagcct cttagatagt gatgaaaga catatttgaa ttggttgta cagaggccag 60
gccagtctcc 70

<210> SEQ ID NO 152
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 152

ttacaacaga ggcttgcca ggctccaaag cacctaattgt atcagggtgc caaactggac 60
cctggcatcc 70

<210> SEQ ID NO 153
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 153

atatagtaat ggaaaaacct atttgaattg gttattacag aggccaggcc agtctccaaa 60
gcgctaatc 70

<210> SEQ ID NO 154
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 154

caggctagt cagagccttg aaaacagtaa tggaacacc tatttgaact ggtacctcca 60
gaaaccaggc 70

<210> SEQ ID NO 155
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 155

catccctgtc catggctata ggagaaaaag tcaccatcag atgcataacc agcactgata 60
ttgatgatga 70

<210> SEQ ID NO 156
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 156

acattggtag tagcttaaac tggcttcagc aggaaccaga tggaactatt aaagcctga 60
tctagccac 70

-continued

<210> SEQ ID NO 157
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 157

cctgtccgtg gctacaggag aaaaagtcac taccagatgc ataaccagca ctgatattga 60
tgatgatatg 70

<210> SEQ ID NO 158
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 158

gggagacaga ataaccatca ctggccaggc aactcaagac attgttaaga atttaaactg 60
gtatcagcag 70

<210> SEQ ID NO 159
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 159

ctctcaccat tagcaacctg gagcaagaag atattgccac ttacttttgc caacagggta 60
atagcgttcc 70

<210> SEQ ID NO 160
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 160

ttgcagcaga aaccagggaa atcatttaag ggcctgatct atcatggaac caacttggaa 60
gatggagttc 70

<210> SEQ ID NO 161
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 161

tctgggagaa agtgtcacca tcacatgcct ggcaagtcag accattggta catggttagc 60
atggtatcag 70

<210> SEQ ID NO 162
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 162

ccgggcaagt caggacatcc atggttattt aaacttgttt cagcagaaac caggtgaaac 60
tattaaacac 70

<210> SEQ ID NO 163
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 163
ttctctcacc atcagcaacc tggaaacctga agatattgcc acttactatt gtcagcagta 60
tagtaagctt 70

<210> SEQ ID NO 164
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 164
ctagtcagag cattgtacat agtaatggaa acacctatTT agaatggTAC ctgcagaaac 60
caggccagtc 70

<210> SEQ ID NO 165
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 165
cactcaagat cagcacaata aagcctgagg acttgggaat gtattactgc ttacaaggta 60
cacatcagcc 70

<210> SEQ ID NO 166
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 166
agatcaagcc tctatctctt gcaagtctac taagagtctt ctgaatagtg atggattcac 60
ttatttggac 70

<210> SEQ ID NO 167
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 167
aaattagtgg ttacttaagc tggcttcagc agaaaccaga tggaactatt aaacgcctga 60
tctacgccgc 70

<210> SEQ ID NO 168
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 168
cagtctctct tgtcgggcta gtcagggcat tagaggaat ttagactggT atcagcagaa 60
accaggtgga 70

<210> SEQ ID NO 169
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 169

-continued

gcagaaagca gagcaagttc cccggctcct tatccatagt gcctccacta gggccggtgg 60
tgtcccagtc 70

<210> SEQ ID NO 170
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 170

agtattctct caagatcagt agcctgcctc ctgacgatgt tgcaacgtat tactgtcaaa 60
atgtgttaag 70

<210> SEQ ID NO 171
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 171

accaacacaa gcctggaaaa ggtcctagcc tgctcataca ttacacatct acattacagc 60
caggcatccc 70

<210> SEQ ID NO 172
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 172

ctccttttct gtatctctag gagacagagt caccattact tgcaaggcaa gtgaggacat 60
atataatcgg 70

<210> SEQ ID NO 173
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 173

ctacttgtct gtatctctag gaggcagagt caccattact tgcaaggcaa gtgaccacat 60
taataattgg 70

<210> SEQ ID NO 174
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 174

ccagaaata ttctaaact attgatctat aaggcttcca acttgcacac aggcgtccca 60
tcaaggttta 70

<210> SEQ ID NO 175
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 175

tattgtgatg acgcaggctg cattctccaa tccagtcact ottggaacat cagcttccat 60
ctcctgcagg 70

-continued

<210> SEQ ID NO 176
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 176
atattgtgat gactcaggct gcaccctctg tacctgtcac tcctggagag tcagtatcca 60
tctcctgcag 70

<210> SEQ ID NO 177
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 177
tctagtaaga gtctcctata taaggatggg aagacatact tgaattggtt tctgcagaga 60
ccaggacaat 70

<210> SEQ ID NO 178
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 178
tgacttgcca ggcaagtcag ggcactagca ttaatttaaa ctggtttcag caaaaaccag 60
ggaaagctcc 70

<210> SEQ ID NO 179
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 179
aattgtgctc actcagtctc cagccatcac agctgcatct ctggggcaaa aggtcaccat 60
cacctgcagt 70

<210> SEQ ID NO 180
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 180
cccggggaga agatcactat cacctgcagt gccagctcaa gtataagttc caattacttg 60
cattgtatc 70

<210> SEQ ID NO 181
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 181
gctcaagtat aagttccagc aacttgcaact ggtaccagca gaagtcagaa acctcccca 60
aacctggat 70

<210> SEQ ID NO 182
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 182
ttacttgcac tgggtaccagc agaagtcagg cgcttccccc aaacccttga ttcataggac 60
atccaacctg 70

<210> SEQ ID NO 183
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 183
ctcaagtgtg agttacatgc actggtacca gcagaagtca ggcacctccc ccaaaagatg 60
gatttatgac 70

<210> SEQ ID NO 184
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 184
aggatcctcg cccaaacctt ggatttatga cacatccaac ctggcttctg gattccctgc 60
tcgcttcagt 70

<210> SEQ ID NO 185
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 185
ccagctcaag tataagttac atgcactggt accagcagaa gccaggcacc tcccccaaaa 60
gatggattta 70

<210> SEQ ID NO 186
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 186
cttcacccat tgtaagagc ttcaacagga atgagtgtta gagacaaagg tcctgagacg 60
ccaccaccag 70

<210> SEQ ID NO 187
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 187
agaaacatgc ccaagtgtat ccttgggtgct tttgectacc atagcccttc tctctaccct 60
caaaatgcac 70

<210> SEQ ID NO 188
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 188

-continued

ccgtgtttcc accttcctct gaggagctca aggaaaacaa agccacactg gtgtgtctga 60
tttccaactt 70

<210> SEQ ID NO 189
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 189

aatcccttct ttcattcaca caggtcagcc caagtccact cccacactca ccatgtttcc 60
accttcccct 70

<210> SEQ ID NO 190
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 190

cgtagcaccgc aagtgtctct agggggactg ttactgagct gcgttttaca ccctttcttt 60
gacaaaacct 70

<210> SEQ ID NO 191
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 191

aggccaatct ccaagggccc taatttataa ggtttctaac tgggactctg gggcccaga 60
cagattcagc 70

<210> SEQ ID NO 192
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 192

agctacttag cctggtacca gcagaaacct ggcttggcgc ccaggctoct catctatgat 60
gcatccagca 70

<210> SEQ ID NO 193
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 193

tcctctctgt gactccaggg gagaaagtc ccatcacctg ccaggccagt gaaggcattg 60
gcaactactt 70

<210> SEQ ID NO 194
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 194

aggccaatct ccaagggccc taatttataa ggtttctaac cgggactctg gggcccaga 60
cagattcagc 70

-continued

<210> SEQ ID NO 195
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 195
ctatttgat tggtaacctgc agaagccagg ccagctctcca cagctcctaa tctatgaagt 60
ttccagccgg 70

<210> SEQ ID NO 196
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 196
tatttggtt ctaatcgggc ctccggggtc cctgacaggt tcagtggcag tggatcaggc 60
acagatttta 70

<210> SEQ ID NO 197
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 197
atttgattg gtacctgcag aagccaggcc agcctccaca gctcctgatc tatgaagttt 60
ccaaccggtt 70

<210> SEQ ID NO 198
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 198
aaagttccta agctcctgat ctatgctgca tccactttgc aatcaggggt cccatctcgg 60
ttcagtggca 70

<210> SEQ ID NO 199
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 199
tccaagactc ctaatttata agatttctaa ccggttctct ggggtcccag acagattcag 60
tggcagtggg 70

<210> SEQ ID NO 200
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 200
ctgcccggcc agtcagagca ttggtagtag cttacactgg taccagcaga aaccagatca 60
gtctccaaag 70

<210> SEQ ID NO 201
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 201
aaattgtggt gacgcagtct ccaggcacc tgtctttgtc tccaggggaa agagccaccc 60
tctcctgcag 70

<210> SEQ ID NO 202
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 202
ttagaaatga ttaggctgg tatcagcaga aaccagggaa agcccctaag cgctgatct 60
atgctgcatc 70

<210> SEQ ID NO 203
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 203
atacacctat ttgtattggt ttctgcagaa agccaggcca gtctccacac tcctgatcta 60
tgaagtttcc 70

<210> SEQ ID NO 204
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 204
gatttcacac tgaaaatcag cagggtgaa gctgaggatg tcggggttta ttactgcacg 60
caagctacac 70

<210> SEQ ID NO 205
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 205
ccctcacaat taataacata gaatctgagg atgctgcata ttacttctgt ctacaacatg 60
ataatttccc 70

<210> SEQ ID NO 206
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 206
tccctggctg tgtctctggg cgagagggcc accatcaact gcaagtccag ccagagtgtt 60
ttatacagct 70

<210> SEQ ID NO 207
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 207

-continued

ggcgagtcag ggcattagca attatntagc ctggtttcag cagaaaccag gaaagcccc 60
taagtcctg 70

<210> SEQ ID NO 208
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 208

cagctactta acctggtatc agcagaaacc tggccaggcg cccaggctcc tcatctatgg 60
tgcattccacc 70

<210> SEQ ID NO 209
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 209

tcaccatcag cagcctgcag cctgaagatt ttgcaactta ttactgtcta caagattaca 60
attaccctcc 70

<210> SEQ ID NO 210
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 210

agacagagtc accatcaact gccgggccag tcagagtatt agtagctggt tggcctggta 60
tcagcagaaa 70

<210> SEQ ID NO 211
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 211

tcgggcgagg cagggcatta gcaattatct agcctggttt cagcagaaac cagggaaagt 60
ccctaagcac 70

<210> SEQ ID NO 212
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 212

ctggttagcc tggatcagc agaaaccaga gaaagccct aagtcctga tctatgctgc 60
atccagtttg 70

<210> SEQ ID NO 213
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 213

tcaccatcag cagcctgcag tctgaagatt ttgcagttta ttactgtcag cagtataata 60
actgacctcc 70

-continued

<210> SEQ ID NO 214
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 214

ctcaccatca gcagcctgca gcctgaagat ttgcaactt attactgtca acagttaa 60
aattaccctc 70

<210> SEQ ID NO 215
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 215

agatttcaact ctcaactatca gcagcctgca gcctgaagat ttgcaactt actattgtca 60
acaggctaac 70

<210> SEQ ID NO 216
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 216

tcaccatcag cagcctgcag tctgaagatt ttgcagttta ttactgtcag cagtataata 60
actggcctcc 70

<210> SEQ ID NO 217
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 217

gtgggcctgg gacagacttc actctcacca tcagcagcct agagcctgaa gatattgcag 60
tttattactg 70

<210> SEQ ID NO 218
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 218

gaaaccaggg aaatccccta agctcttctc ctatgatgca aaagatttgc accctggggt 60
ctcatcgagg 70

<210> SEQ ID NO 219
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 219

gtatcagcaa aaaccagcaa aagcccoctaa gctcttcac tattatgcat ccagtttgca 60
aagtggggtc 70

<210> SEQ ID NO 220
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 220
tccttactct ctgcactctac aggagacaga gtcacatca gttgtcggat gagtcagggc 60
attagcagtt 70

<210> SEQ ID NO 221
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 221
cagctactta tcctggtacc agcagaaacc tgggcaggct cccaggctcc tcatctatgg 60
tgcatecacc 70

<210> SEQ ID NO 222
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 222
ctcacatca gcagcctgca gcctgaagat tttgcaactt attactgtca acagtttaat 60
agttaccctc 70

<210> SEQ ID NO 223
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 223
gatctgggac agatttcact ctcacatca gcagcctgca gcctgaagat tttgcaactt 60
actattgtca 70

<210> SEQ ID NO 224
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 224
aaagagccac cctctcctgc agggccagtc agagtgttag cagctactta gcctggtacc 60
aacagaaacc 70

<210> SEQ ID NO 225
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 225
tctcacaatc agcagcctgc agcctgaaga tttgcaact tattactgtc aacagcttaa 60
tagttaccct 70

<210> SEQ ID NO 226
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 226

-continued

cattctctgc atctacagga gacagagtca ccatcacttg tcgggcgagt cagggtatta 60
gcagttattt 70

<210> SEQ ID NO 227
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 227

atctatacgc tttcctatcg ggcctctgga gtcccagaca ggttcagtgg cagtgggtca 60
ggcactgatt 70

<210> SEQ ID NO 228
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 228

tctcaccatc agcagtctgc aacctgaaga ttttgcaact tactactgtc aacagagtta 60
cagtaccctt 70

<210> SEQ ID NO 229
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 229

tcactatcag cagcctgcag cctgaagatg ttgcaactta ttacggtaa cggacttaca 60
atgccctcc 70

<210> SEQ ID NO 230
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 230

acgatgcatc caatttgaa acaggggtcc catcaagggt cagtggaagt ggatctggga 60
cagattttac 70

<210> SEQ ID NO 231
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 231

caggaaaggc tcccaaactc ctcatctatt atgatgatct gctgccctca ggggtctctg 60
accgattctc 70

<210> SEQ ID NO 232
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 232

atcactgggc tccaggctga ggatgaggct gattattact gccagtccta tgacagcagc 60
ctgagtgggt 70

-continued

<210> SEQ ID NO 233
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 233
gtcaccatct cttgttctgg aagcagctcc aacatcgga gtaatactgt aaactggtac 60
cagcagctcc 70

<210> SEQ ID NO 234
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 234
aattatgtat actggtacca gcagctccca ggaacggccc ccaaactcct catctatagt 60
aataatcagc 70

<210> SEQ ID NO 235
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 235
ccatcactgg actccagtct gaggatgagg ctgattatta ctgcaaagca tgggataaca 60
gcctgaatgc 70

<210> SEQ ID NO 236
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 236
atcaccggac tccagactgg ggacgaggcc gattattact gcggaacatg ggatagcagc 60
ctgagtgtctg 70

<210> SEQ ID NO 237
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 237
cgtctctggg ctccaggctg aggatgaggc tgattattac tgcagctcat atgcaggcag 60
caacaatttc 70

<210> SEQ ID NO 238
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 238
accaaggagc agcttggtctg cagcagcacc agggccaccc tcccaaactc ctatcctaca 60
ggaataacaa 70

<210> SEQ ID NO 239
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 239
tctccgggga agacggtaac catctcctgc acccgcagca gtggcagcat tgccagcaac 60
tatgtgcagt 70

<210> SEQ ID NO 240
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 240
catctctggg ctccaggctg aggatgaggc tgattattac tgctgctcat atgcaggcag 60
ctacactttc 70

<210> SEQ ID NO 241
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 241
catgatttat gaggtcagta atcggccctc aggggtttct aatcgcttct ctggctccaa 60
gtctggcaac 70

<210> SEQ ID NO 242
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 242
ttggtagtta taaccgtgtc tcttgggtacc agcagccccc aggcacagcc cccaaactca 60
tgatttatga 70

<210> SEQ ID NO 243
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 243
aatctctggg ctccaggctg aggacgaggc tgattattac tgctgctcat atgcaggtag 60
tagcactttc 70

<210> SEQ ID NO 244
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 244
cgttggggat tatgatcatg tcttctggta ccaaagcgt ctcagcacta cctccagact 60
cctgatttac 70

<210> SEQ ID NO 245
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 245

-continued

tccgtgtccc caggacagac agccagcatc acctgctctg gagataaatt gggggataaa 60
tatgcttgct 70

<210> SEQ ID NO 246
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 246

aaaaaatatg cttattggta ccagcagaag ccaggccagt tcctgtgct ggtgatatat 60
aaagacagcg 70

<210> SEQ ID NO 247
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 247

acagacagtc aggatcacat gccaaaggaga cagcctcaga agctattatg caagctggta 60
ccagcagaag 70

<210> SEQ ID NO 248
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 248

catcagcagg gtcgaaagccg gggatgagcc cgactattac tgtcaggtgt gggatagtag 60
tagtgatcat 70

<210> SEQ ID NO 249
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 249

ccctgagttg gtgatatacg aagatagtg gcggtaccct ggaatccctg aacgattctc 60
tgggtccacc 70

<210> SEQ ID NO 250
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 250

acagtcacgt tgaccatcag tggagtccag gcagaagatg aggctgacta ttactgtcaa 60
tcagcagaca 70

<210> SEQ ID NO 251
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 251

ccttgaccat cagcggggcc caggttgagg atgaggctga ctattactgt tactctgccc 60
ctgacaacaa 70

-continued

<210> SEQ ID NO 252
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 252
gaccatcagc agagcccaag ccgggatga ggctgactat tactgtcagg tgtgggacag 60
cagcactgca 70

<210> SEQ ID NO 253
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 253
tcagtggggc ccaggtggag gatgaagctg actactactg ttactcaaca gacagcagtg 60
gtaatcatag 70

<210> SEQ ID NO 254
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 254
tccaaccag ggaaccaccg caccctaacc atcagcagga tcgaggctgg ggatgaggct 60
gactattact 70

<210> SEQ ID NO 255
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 255
gacactgtca ggtgtgcagc ctgaggacga ggctgagtat tactgcctgc tctactatgg 60
tgggtctcag 70

<210> SEQ ID NO 256
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 256
tcattatccc tactggttcc agcagaagcc tggccaagcc ccaggacac tgatttatga 60
tacaagcaac 70

<210> SEQ ID NO 257
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 257
gaacaaagct gcctcacca tcacgggggc ccaggcagat gatgaatctg attattactg 60
tgtgctgtat 70

<210> SEQ ID NO 258
<211> LENGTH: 70

-continued

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 258
accttcctcc tccgcatctc ctggagaatc cgccagactc acctgcacct tgcccagtga 60
catcaatggt 70

<210> SEQ ID NO 259
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 259
gtaccagcag aagccaggga gtcctcccca gtatctcctg aggtacaaat cagactcaga 60
taagcagcag 70

<210> SEQ ID NO 260
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 260
gtaccagcag aagccagaga gccctccccc gtatctcctg agctactact cagactcaag 60
taagcatcag 70

<210> SEQ ID NO 261
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 261
atgctgagca gtggcttcag tgttggggac ttctggataa ggtggtacca acaaaagcca 60
gggaaccctc 70

<210> SEQ ID NO 262
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 262
acctggggtc cccagtcgag tctctggctc caaggagacc tcaagtaaca cagcgttttt 60
gtcctctct 70

<210> SEQ ID NO 263
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 263
tgagcacagc acctacacca tcgaatgta tcaacagaga ccaggagggt cccccagta 60
tataatgaag 70

<210> SEQ ID NO 264
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 264

-continued

atcaagaaca tccaggaaga agatgagagt gactaccact gtggggcaga ccatggcagt 60
gggagcaact 70

<210> SEQ ID NO 265
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 265

ccaggaagg cccctcgga cttgatgaag cttgaaggta gtggaagcta caacaagggg 60
agcggagttc 70

<210> SEQ ID NO 266
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 266

gagaagggcc ctccgtactt gatgaagctt aacagtgatg gcagccacag caagggggac 60
gggatccctg 70

<210> SEQ ID NO 267
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 267

catgtcgagc aagtgagaac atttactaca gtttagcatg gtatcagcag aagcaagggg 60
aatctcc 67

<210> SEQ ID NO 268
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 268

ttcacaatta tttagcatgg tatcagcaga aacagggaaa atctcctcag ctctctgtct 60
ataatgc 67

<210> SEQ ID NO 269
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 269

cgagcaagtg agaatattta cagttattta gcatggatc agcagaaaca gggaaaatct 60
cctcagc 67

<210> SEQ ID NO 270
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 270

cgagcaagtg agaatattta cagtaattta gcatggatc agcagaaaca gggaaaatct 60
cctcagc 67

-continued

<210> SEQ ID NO 271
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 271

tggatatcaac agaaaccagg acaatctcct aaactactga tttactcggc atccaatcgg 60
tacactg 67

<210> SEQ ID NO 272
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 272

gatctgggac agatttcaact ctcaccatta gcaatgtgca atctgaagac ctggcagatt 60
atttctg 67

<210> SEQ ID NO 273
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 273

ctcacatca gcaatgtgca gtctgaagac ttggcagagt atttctgtca gcaatataac 60
agctatc 67

<210> SEQ ID NO 274
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 274

ctttcaccat cagcagtggt caggctgaag acctggcagt ttattactgt cagcaacatt 60
atagtac 67

<210> SEQ ID NO 275
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 275

caaggccagt gagaatgtgg gtacttatgt atcctggtat caacagaaac cagagcagtc 60
tcctaaa 67

<210> SEQ ID NO 276
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 276

cagatttcac tctcaccatt agcaatgtgc agtctgaaga cttggcagat tatttctgtc 60
agcaatatag 70

<210> SEQ ID NO 277
<211> LENGTH: 69

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 277
attatactct caccatcagc agtgtgcagg ctgaagacct ggcactttat tactgtcagc 60
aacattata 69

<210> SEQ ID NO 278
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 278
caaggccagt gagaatgtgg gtacttatgt atcctgttat caacagaaac cagagcagtc 60
tcctaaa 67

<210> SEQ ID NO 279
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 279
cagtctccta aactgctgat atactatgca tccaatcgct aactggagt cctgacgac 60
ttcactg 67

<210> SEQ ID NO 280
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 280
gtaccaacag aaaccaggac agccacccaa actcctcatc tatgctgcat ccaacgtaga 60
atctggg 67

<210> SEQ ID NO 281
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 281
gtctaggaca gacttcaccc tcaccattga tcctgtggag gctgatgatg ctgcaaccta 60
ttactgt 67

<210> SEQ ID NO 282
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 282
gtaccaacag aaaccaggac agccacccaa actcctcatc tatcttgcat ccaacctaga 60
atctggg 67

<210> SEQ ID NO 283
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 283

-continued

ctcaacatcc atcctatgga ggaggatgat actgcaatgt atttctgtca gcaaagtaag 60

gaggttc 67

<210> SEQ ID NO 284

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 284

ctgcagagcc agccagagtg tcgattataa tggaattagt tatatgcact ggtccaaca 60

gaaacca 67

<210> SEQ ID NO 285

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 285

gtaccaacag aaaccaggac agccacccaa actcctcatc tatgctgcat ccaatctaga 60

atctggg 67

<210> SEQ ID NO 286

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 286

ttcagtgcca gtgggtctag gacagacttc accctcacca ttaatcctgt ggaggctgat 60

gatgttg 67

<210> SEQ ID NO 287

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 287

ctcaacatcc atcctgtgga ggaggaggat actgcaacat attactgtca gcacagttgg 60

gagattc 67

<210> SEQ ID NO 288

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 288

ctgagtcaga cttcactctc accatcgatc ctgtggagga agatgatgct gcaatgtatt 60

actgtat 67

<210> SEQ ID NO 289

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 289

tctgggacag atttcactct gaccatcagc agtgtacagg ttgaagacct cacacattat 60

tactgtg 67

-continued

<210> SEQ ID NO 290
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 290
gagtatttac aagaacctac actggtatca acagaaatca catcggtctc caaggcttct 60
catcaagtat g 71

<210> SEQ ID NO 291
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 291
gggtcagatt tactctcag tatcaacagt gtggaacctg aagatgttg agtgattac 60
tgtcaaa 67

<210> SEQ ID NO 292
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 292
tggatcagg acagatttca ctctcagtat caacagtgtg gagactgaag attttggat 60
gtatttct 68

<210> SEQ ID NO 293
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 293
agtcaaagta ttagcaacta cctacactgg tatcaacaaa aatcacatga gtctccaagg 60
cttctca 67

<210> SEQ ID NO 294
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 294
tttagtggca gtggatcagg gacagatddd actcttagca tcaacagtgt ggagtctgaa 60
gatattg 67

<210> SEQ ID NO 295
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 295
taccagcaga agtcagatgc ctccccaaa ctatggattd attacacatc caacctggct 60
cctggag 67

<210> SEQ ID NO 296
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 296
gatctcttac tctctcacia tcagcagcat ggaggctgaa aatgatgcaa cttattactg 60
ccagcag 67

<210> SEQ ID NO 297
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 297
ctcttactct ctcaaatca gcagtgtgga ggctgaagat gctgccactt attactgcc 60
gcagtac 67

<210> SEQ ID NO 298
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 298
catctgatag gtactctgga gtccctgatc gtttcatagg cagtggatct gtgacagatt 60
tcactct 67

<210> SEQ ID NO 299
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 299
gagagaaggt cactatgagc tgcaagtcca gtcagagtct gttaaacagt ggaatcaaa 60
agaacta 67

<210> SEQ ID NO 300
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 300
gaaggtcact atgagctgca aatccagtca gactctgctc aacagtagaa cccgaaagaa 60
ctacttg 67

<210> SEQ ID NO 301
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 301
gacagaaggt cactatgagc tgcaagtcca gtcagagcct tttaaatagt agcaatcaaa 60
agaacta 67

<210> SEQ ID NO 302
<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 302

-continued

gcaggagaaa aggtcactat gagctgtaag tccagtcaaa gtgttttata cagttcaaat 60
cagaagaac 69

<210> SEQ ID NO 303
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 303

gagagaaggt cactatgagc tgcaagtcca gtcagagtct gttaaacagt ggaatcaaa 60
agaacta 67

<210> SEQ ID NO 304
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 304

ttggagagaa gggtactatg agctgcaagt ccagttagag ccttttatat agtagcaatc 60
aaaagaacta ctt 73

<210> SEQ ID NO 305
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 305

gatctcctaa aatgctgata atttgggcat ccactagggt atctggagtc cctgatcgct 60
tcatagg 67

<210> SEQ ID NO 306
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 306

tctcctggag aaaccattac tattaattgc aggcaagta agagcattag caaatattta 60
gcctggtatc aag 73

<210> SEQ ID NO 307
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 307

caaatgttc tcaccagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc 60
atatacct 67

<210> SEQ ID NO 308
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 308

ctggaaactc ttactctctc acgatcagca gcatggaggc tgaagatggt gccacttatt 60
actgttt 67

-continued

<210> SEQ ID NO 309
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 309

caatcatgtc tgcattctct ggggagaagg tcaccatgac ctgcagtgcc agatcaagtg 60
taagttc 67

<210> SEQ ID NO 310
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 310

caaattgttc tcaccagtc tccagcaatc atgtctgcat ctctgggga gaaggtcacc 60
ttgacct 67

<210> SEQ ID NO 311
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 311

cacttctccc aaactcttga tttatagcac atccaacctg gcttctggag tcccttctcg 60
cttcagt 67

<210> SEQ ID NO 312
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 312

ctttaccac attctggatt tataggacat ccaacctggc tcagaagtc ccagctccct 60
tcagtgg 67

<210> SEQ ID NO 313
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 313

gactctcccc aaaactctgg atttatagca tatccaacct ggcttctgga gtcccagctc 60
gcttcag 67

<210> SEQ ID NO 314
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 314

caaattgttc tcaccagtc tccagcaatc atgtctgcat ctctagggga acgggtcacc 60
atgacct 67

<210> SEQ ID NO 315
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 315
gatcctcccc caaactctgg atttatagca tatccaacct ggcttctgga gtccttgctc 60
gcttcag 67

<210> SEQ ID NO 316
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 316
ctctggattt atttaacatt caacttggct tctggagtcc ctgctcgctt cagtggcagt 60
gggtctg 67

<210> SEQ ID NO 317
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 317
ctctcacaat cagcagagtg gaggtgaag atgctgccac ttattactgc cagcagtgga 60
gtagtaa 67

<210> SEQ ID NO 318
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 318
catctttctc ttcacaaac aacagcatgg aggctgaaga tgttgccact tattactgtc 60
agcaaag 67

<210> SEQ ID NO 319
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 319
caagtgtaag ttacatgcac tggttccagc agaagccagg cacttctccc aaactctgga 60
tttatag 67

<210> SEQ ID NO 320
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 320
catctccagg ggagaaggtc accatgacct gcagtgccag ctcaagtgta agttacatgt 60
actggta 67

<210> SEQ ID NO 321
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 321

-continued

cttcagtggc agtggatctg ggacctctta ttctctcaca atcagcagca tggaggctga 60

agatgct 67

<210> SEQ ID NO 322

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 322

catctccagg ggagaaggtc accatgacct gcagtgccag ctcaagtga agttacatgt 60

actggta 67

<210> SEQ ID NO 323

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 323

gaggggagaa ggtcaccatc acctgccctg ccagctcaag tataagttcc aattacttac 60

actggta 67

<210> SEQ ID NO 324

<211> LENGTH: 68

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 324

tggatctggg caagattatt ctctcacat cagcagcctg gagtatgaag atatgggaat 60

ttattatt 68

<210> SEQ ID NO 325

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 325

catctcttgc agatctagtc agagccttgt acacagtaat ggaaacacct atttacattg 60

gtacctg 67

<210> SEQ ID NO 326

<211> LENGTH: 68

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 326

ccatctcttg cagatctagt cagagccttg tacacagtaa tggaaacacc tatttatatt 60

ggtacctg 68

<210> SEQ ID NO 327

<211> LENGTH: 67

<212> TYPE: DNA

<213> ORGANISM: Mus musculus

<400> SEQUENCE: 327

ctcttagata gtgatggaaa gacatatttg aattggttgt tacagaggcc aggccagtct 60

ccaaagc 67

-continued

<210> SEQ ID NO 328
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 328

aaactggacc ctggcatccc tgacaggttc agtggcagtg gatcagaaac agattttaca 60
cttaaaat 68

<210> SEQ ID NO 329
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 329

ctatttgaat tggttattac agaggccagg ccagtctcca aagcgcctaa tctatctggt 60
gtctaaa 67

<210> SEQ ID NO 330
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 330

ctccatctct tgcaggctca gtcagagcct tgaaaacagt aatggaaaca cctatttgaa 60
ctggtac 67

<210> SEQ ID NO 331
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 331

ggaacctcct aagctcctta tttcagaagg caatactctt cgtcctggag tcccacccg 60
attctcc 67

<210> SEQ ID NO 332
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 332

ggacattggt agtagcttaa actggcttca gcaggaacca gatggaacta ttaaacgcct 60
gatctac 67

<210> SEQ ID NO 333
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 333

ggaacctcct aagctcctta tttcagaagg caatactctt cgtcctggag tcccacccg 60
attctcc 67

<210> SEQ ID NO 334
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 334
tctgggagac agaataacca tcacttgcca ggcaactcaa gacattgtta agaatttaa 60
ctgggat 67

<210> SEQ ID NO 335
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 335
ttcagtgcca gtgggtctgg aacagattat tctctcacca ttagcaacct ggagcaagaa 60
gatattg 67

<210> SEQ ID NO 336
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 336
cagcagaaac cagggaaatc atttaagggc ctgatctatc atggaaccaa cttggaagat 60
ggagttc 67

<210> SEQ ID NO 337
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 337
gaccattggt acatggtag catgggatca gcagaaacca gggaaatctc ctcagtcct 60
gatttat 67

<210> SEQ ID NO 338
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 338
acctgatcta tgaacatcc aatttagatt ctggtgtccc aaaaagggtc agtggcagta 60
ggtctgg 67

<210> SEQ ID NO 339
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 339
ttattctctc accatcagca acctggaacc tgaagatatt gccacttact attgtcagca 60
gtatagt 67

<210> SEQ ID NO 340
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 340

-continued

ggagatcaag cctccatctc ttgcagatct agtcagagca ttgtacatag taatggaaac 60
acctatttag aat 73

<210> SEQ ID NO 341
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 341

gatttcacac tcaagatcag cacaataaag cctgaggact tggaatgta ttactgctta 60
caaggta 67

<210> SEQ ID NO 342
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 342

ctcaagatca gcagagtga ggctgaggat ttgggagttt attattgctt ccagagtaac 60
tatcttc 67

<210> SEQ ID NO 343
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 343

ggaaattagt ggttacttaa gctggcttca gcagaaacca gatggaacta ttaaagcct 60
gatctac 67

<210> SEQ ID NO 344
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 344

ctagtcaggg cattagaggt aatttagact ggtatcagca gaaaccaggt ggaactatta 60
aactcctg 68

<210> SEQ ID NO 345
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 345

gaaacaacac aggctccagc ttctctgagt tttctcttg gtgaaacagc aacctgtca 60
tgcaggtc 68

<210> SEQ ID NO 346
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 346

caagtgagaa tatttacggt gctttaaatt ggtatcagcg gaaacagga aaatctctc 60
agctcct 67

-continued

<210> SEQ ID NO 347
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 347

ctgctcatac attacacatc tacattacag ccaggcatcc catcaagggt cagtggaagt 60
gggtctg 67

<210> SEQ ID NO 348
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 348

gttccttcaa gattcagtgg cagtggatct ggaaaggatt aactctcag cattaccagt 60
cttcaga 67

<210> SEQ ID NO 349
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 349

gacatccaga tgacacaatc ttcactctac ttgtctgtat ctctaggagg cagagtcacc 60
attactt 67

<210> SEQ ID NO 350
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 350

ggaaatattc ctaaactatt gatctataag gttccaact tgcacacagg cgtcccatca 60
aggttta 67

<210> SEQ ID NO 351
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 351

gatattgtga tgacgcaggc tgcattctcc aatccagtca ctcttgaac atcagcttcc 60
atctcct 67

<210> SEQ ID NO 352
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 352

ctgagaatca gtagagtga ggctgaggat gtgggtgttt attactgtat gcaacatcta 60
gaatatcc 68

<210> SEQ ID NO 353
<211> LENGTH: 67

-continued

<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 353
ctggaaatca gtagagtcaa ggctgaggat gtgggtgtgt attactgtca acaacttgta 60
gagtatc 67

<210> SEQ ID NO 354
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 354
tctcaccatc agcagcctgg aggatgaaga tatggcaact tatttctgtc tacagcatag 60
ttatctc 67

<210> SEQ ID NO 355
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 355
catggattta tgaatatcc aaactggctt ctggagtccc agctcgcttc agtggcagtg 60
ggtctgg 67

<210> SEQ ID NO 356
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 356
caattacttg cattggtatc agcagaagcc aggattctcc cctaaactct tgatttatag 60
gacatcc 67

<210> SEQ ID NO 357
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 357
cttctggagt ccctgttcgc ttcagtggca gtggatctgg gacctcttat tctctcacia 60
tcagcag 67

<210> SEQ ID NO 358
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 358
ggtctgggac ctcttactct ctcacaatca gcagcgtgga ggctgaagat gatgcaactt 60
attactg 67

<210> SEQ ID NO 359
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 359

-continued

ccccaaaagat ggatttatga cacatccaaa ctggcttctg gagtccctgc tcgcttcagt 60

ggcagtg 67

<210> SEQ ID NO 360
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 360

caaatcttc tcacccagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc 60

atgacct 67

<210> SEQ ID NO 361
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 361

ccccaaaagat ggatttatga cacatccaaa ctggcttctg gagtccctgc tcgcttcagt 60

ggcagtg 67

<210> SEQ ID NO 362
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 362

cttcagtggc agtggatctg ggacctcta ttctctcaca atcagcagca tggaggctga 60

agatgct 67

<210> SEQ ID NO 363
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 363

aagtactggg gctgttacaa ctagtaacta tgccaactgg gtccaagaaa aaccagatca 60

tttattc 67

<210> SEQ ID NO 364
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 364

gtactggggc tgttacaact agtaactatg ccaactgggt tcaagaaaa ccagatcatt 60

tattcact 68

<210> SEQ ID NO 365
<211> LENGTH: 67
<212> TYPE: DNA
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 365

ttagcatttc caacatccag cctgaagatg aagcaatata catctgtggt gtgggtgata 60

caattaa 67

-continued

```

<210> SEQ ID NO 366
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 366

tctgttcaag ccgaggcadc cttt

```

24

```

<210> SEQ ID NO 367
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 367

tccaaagcgt gttcccttcg gtat

```

24

We claim:

1. A microarray comprising a plurality of oligonucleotide species, each species capable of hybridizing to a polynucleotide comprising a sequence or a complement thereof, the sequence encoding at least a portion of a light chain variable region, and wherein each of the plurality of oligonucleotide species is at least 20 nucleotides long.

2. The microarray of claim 1, wherein the light chain variable region is a vertebrate light chain variable region.

3. The microarray of claim 1, wherein the light chain variable region is a human light chain variable region.

4. The microarray of claim 1, wherein each of the plurality of oligonucleotide species is at least 40 nucleotides long.

5. The microarray of claim 1, wherein each of the plurality of oligonucleotide species is at least 60 nucleotides long.

6. The microarray of claim 1, wherein the plurality of oligonucleotide species comprises at least two oligonucleotide species substantially similar to the oligonucleotides of Table 2, Table 3, Table 4, or Table 5, or complements of the oligonucleotides of Table 2, Table 3, Table 4, or Table 5.

7. The microarray of claim 1, wherein the plurality of oligonucleotide species comprise at least 20 of the oligonucleotides of Table 2, Table 3, Table 4, or Table 5, or complements of the oligonucleotides of Table 2, Table 3, Table 4, or Table 5.

8. The microarray of claim 1, wherein each oligonucleotide species is immobilized at a distinct address on a substrate.

9. The microarray of claim 1, wherein at least one of the light chain variable regions is associated with a disease.

10. The microarray of claim 9, wherein the at least one light chain variable region is associated with a systemic autoimmune disease.

11. The microarray of claim 1, wherein the plurality of oligonucleotide species comprises an oligonucleotide comprising a sequence encoding at least a portion of a light chain variable region of mBT20, mBW20, mGJ38C, mVLX, m21-4, m12-38, m12-46, O8, O18, L25, B2, L11, L22, L10, V2-8, V2-14, V2-15, V2-19, A5, or complements of mBT20, mBW20, mGJ38C, mVLX, m21-4, m12-38, m12-46, O8, O18, L25, B2, L11, L22, L10, V2-8, V2-14, V2-15, V2-19, or A5.

12. A method of characterizing the light chain variable gene expression in a subject comprising:

- a) isolating B cells from the subject;
- b) preparing target polynucleotides from the B cells;
- c) hybridizing the target polynucleotides to a microarray comprising a plurality of oligonucleotide species at least 20 nucleotides long, each species capable of hybridizing to at least one of the target polynucleotides comprising a sequence or a complement thereof, the sequence encoding at least a portion of a light chain variable region; and
- d) detecting the hybridization.

13. A method of identifying light chain variable genes associated with a disease, comprising comparing the light chain variable gene expression in a first subject with the disease to the light chain variable gene expression in a second subject that does not have the disease, a difference in light chain variable gene expression between the first and second subjects indicating that expression of the light chain variable gene is associated with the disease.

14. The method of claim 13, wherein the disease is a systemic autoimmune disease.

15. The method of claim 14, wherein the systemic autoimmune disease is selected from the group consisting of systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease, amyloidosis, and psoriasis.

16. The method of claim 13, wherein the disease is cancer.

17. The method of claim 16, wherein the cancer is a B cell cancer.

18. The method of claim 13, wherein the disease is an immunodeficiency disease.

19. A method of monitoring a disease state in a subject comprising comparing expression in the subject of a light chain variable gene associated with the disease at two or more different time points.

20. A method of evaluating the effect of a therapy or therapeutic agent on expression of a light chain variable gene associated with a disease in a subject, comprising comparing expression of the light chain variable gene expression in the subject before and after treatment.

21. A kit comprising the microarray of claim 1.

* * * * *